Sasayama’s Weblog


2009/11/28 Saturday

D225GÊÑ°ÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 20:46:27

¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø

¤³¤Î¾ðÊó¤Ï11·î28Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ­¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ­»ö¤Ç¤Ï¡¢²¼µ­¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ­»ö½ç¤Ç¤¹¡£

¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ(11·î25Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ(11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ(11·î19Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)

2009ǯ11·î28Æü
¡¡
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¤Çȯ¸«¤ÎD225GÊÑ°Û¥¦¥¤¥ë¥¹¤Ë¤Ä¤¤¤Æ¤Ï¡¢»ä¤Î¥Ö¥í¥°µ­»ö¡Ö¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ¡×¤ò¤´»²¾È¤¤¤¿¤À¤­¤¿¤¤¤¬¡¢¤³¤³¤Ë¤­¤Æ¡¢¥¤¥®¥ê¥¹¤ÎMill Hill¤Ë¤¢¤ëWHO¤ÎÃϰ襻¥ó¥¿¡¼¤ÎNIMR( National Institute for Medical Research) ¤¬¡¢¶âÍËÆü¤Ë¡¢¤³¤ì¤é¤ÎD225GÊÑ°Û¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¤Ï¡¢¸½ºß¤Î¥ï¥¯¥Á¥ó¤Ï¸úÎϤòȯ¤·¤Ê¤¤( D225G Vaccine Failure¡¢¥ï¥¯¥Á¥óÉÔÁ´¡¢¥ï¥¯¥Á¥ó¤òÀܼ路¤Æ¤â½½Ê¬¤Ê¹³ÂΤ¬ÆÀ¤é¤ì¤Ê¤¤)¤È¤Î³Îǧ¤ò¤·¤¿¤¬¡¢¤³¤ì¤Ë¤Ä¤¤¤Æ¤ÎWHO¤«¤é¤Î¸ø¼°Åª¤Ê¸«²ò¤ÎɽÌÀ¤Ï¤µ¤ì¤Ê¤¤¤Þ¤Þ¤Ë¤¢¤ë¤è¤¦¤À¡£(¤³¤Î¥Ú¡¼¥¸¤Î²¼Éô¤Ë¤¢¤ë11·î26Æü¤ÎWHO¤ÎDr Keiji Fukuda»á¤Î¥Ð¡¼¥Á¥ã¥ëµ­¼Ô²ñ¸«»²¾È)

¤¹¤Ê¤ï¤Á¡¢¾åµ­¤Î¥í¥ó¥É¥ó¤ÎMillHill¤Ë¤¢¤ëWHO¤Î¸¦µæ½ê¤Ç³Îǧ¤·¤¿¤È¤³¤í¤Ë¤è¤ë¤È¡¢¥¦¥¯¥é¥¤¥Ê¤«¤é¸¡ÂΤΤҤȤÄA/Lviv/N6/2009¤Ë¡¢¥ï¥¯¥Á¥ó¤ËÂФ·¤ÆÄ㤤¥ê¥¢¥¯¥¿¡¼(ÄãÈ¿±þÍÛÀ­)¤ò»ý¤Ä¥¦¥¤¥ë¥¹¤¬¤¢¤ê¡¢¤½¤Î¾¤Î¥¦¥¤¥ë¥¹¤Ë¤Ï¡¢¥¿¥ß¥Õ¥ëÂÑÀ­¤¬¤¢¤Ã¤¿¤È¤Î¤³¤È¤Ç¤¢¤ë¡£

¤³¤ì¤Ï¡¢D225GÊѰۤˤè¤Ã¤Æ¡¢ÌȱÖÈ¿±þ¤¬²óÈò(ÌȱÖƨÈò¡¢ immunological escape)¤µ¤ì¤¿¤È¤Î¸«Êý¤¬¤µ¤ì¤Æ¤¤¤ë¡£

»²¹Í
¡ÖD225G Evades Immune Response¡×

¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¥Ë¥å¡¼¥è¡¼¥¯¥¿¥¤¥à¥º»æ¤ÎDonald McNeil»á¤Îµ­»ö¡ÖExperts Say Swine Flu Mutations Do Not Warrant New Alarm ¡×¤Ë¤ª¤¤¤Æ¤â¡¢D222GÊÑ°Û¤äD225GÊѰۤˤĤ¤¤Æ¤Î¥ï¥¯¥Á¥óÉÔÁ´·üÇ°¤¬¼¨¤µ¤ì¤Æ¤¤¤ë¡£
»²¹Í¡ÖVaccine Failure Confirmed in New York Times by UK National Institute for Medical Research ¡×

¤Þ¤¿¡¢¤³¤Î¥µ¥¤¥È¡ÖMill Hill Designates Ukraine with D225G a Low Reactor¡× ¤Ç¤Ï¡¢¸½ºß¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤¬¡¢¤â¤¦¤·¤Ð¤é¤¯¤¹¤ë¤È¡¢ÌµÍѤΤâ¤Î¤È¤Ê¤ê¤«¤Í¤Ê¤¤¡¢¤È¤Î¸«Êý¤â¤·¤Æ¤¤¤ë¡£

ÌäÂê¤Ï¡¢¥¦¥¤¥ë¥¹¸¡ÂΤκμ褬¡¢¸½ºß¤Ï¡¢¾åµ¤Æ»¤«¤é¤Î¤ß¤ÎºÎ¼è¤È¤Ê¤Ã¤Æ¤¤¤ë¤È¤³¤í¤«¤é¡¢ÇÙÁÈ¿¥¤Ë¤È¤É¤Þ¤Ã¤Æ¤¤¤ëD225GÊѰۤΥ¦¥¤¥ë¥¹¤¬¡¢È¯¸«¤µ¤ì¤Ë¤¯¤¤¾õÂ֤Ǥ¢¤ê¡¢¸½ºßȯ¸«¤µ¤ì¤Æ¤¤¤ë°Ê¾å¤ÎD225GÊÑ°Û¥¦¥¤¥ë¥¹¤¬¡¢À¤³¦Ãæ¤ËÌ¢±ä¤·¤Æ¤¤¤ë²ÄǽÀ­¤¬¤¢¤ë¤³¤È¡¢¤½¤·¤Æ¡¢¤½¤ì¤ËÂФ¹¤ë¥ï¥¯¥Á¥ó¤¬¡¢D225GÊÑ°Û¡¦D225EÊÑ°Û¡¦D225NÊÑ°Û¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¤Ï¡¢¥ï¥¯¥Á¥óÉÔÁ´¤Ç¤¢¤ë¡¢¤È¤¤¤¦¤³¤È¤Ç¤¢¤ë¡£

¡ÖWHO Silence on D225G Vaccine Mismatch Confuses Media¡×¤Ç¤Ï¡¢
¡Ö4ÇÜÎ̤Υ說¥Á¥ó¤òÀܼ路¤Ê¤±¤ì¤Ð¡¢¥¿¥¤¥¿¡¼(ÎϲÁ¡Ë¤¬Áý²Ã¤·¤Ê¤¤¤È¤¤¤¦¤³¤È¤Ï¡¢¡Ø¥ï¥¯¥Á¥ó¤Î¥ß¥¹¥Þ¥Ã¥Á¡Ù¤È¤â¤¤¤¨¡¢¤³¤Î¥ï¥¯¥Á¥óÀܼï¤Ë¤è¤Ã¤Æ¤Ï¡¢¥¿¥¤¥¿¡¼¤ò¸º¾¯¤µ¤»¤ë¿·¤¿¤ÊÊÑ°Û¤ò¸º¾¯¤¹¤ë¤³¤È¤Ë¤Ï¤Ä¤Ê¤¬¤é¤Ê¤¤¤¬¡¢ÌîÀ¸¥¿¥¤¥×¤ÎÊÑ°Û¥¦¥¤¥ë¥¹¤Î¤ß¤ò¸º¾¯¤µ¤»¤ë¤³¤È¤Ë¤Ä¤Ê¤¬¤ë¡£¤½¤Î·ë²Ì¡¢¥ß¥¹¥Þ¥Ã¥Á¤·¤¿¥ï¥¯¥Á¥ó¤ò³¤±¤Æ»È¤Ã¤Æ¤¤¤¯¤È¡¢¥ï¥¯¥Á¥óÂÑÀ­¥¦¥¤¥ë¥¹¤ÎÁý²Ã¤òÀ¸¤à¤³¤È¤Ë¤Ê¤ë¡£¡×
¤È¤·¤Æ¤¤¤ë¡£

¤Þ¤¿¡¢¥Õ¥é¥ó¥¹¤«¤é¤ÎÊóÆ»¤Ç¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¤Î¥ï¥¯¥Á¥ó¤Ç¤Ê¤±¤ì¤Ð¡¢¥¿¥¤¥¿¡¼(ÎϲÁ¡Ë¤¬Áý²Ã¤·¤Ê¤¤¤È¤ÎÉ÷À⤬ή¤ì¤Æ¤¤¤ë¤è¤¦¤Ç¤¢¤ë¡£
(” Ces nouvelles mutations doivent au contraire inciter tous les Fran½æMais ½æA aller se faire vacciner, avec adjuvant.”¡Ö¤³¤ì¤é¤ÎÊѰۤϡ£µÕ¤Ë¡¢¤¹¤Ù¤Æ¤Î¥Õ¥é¥ó¥¹¿Í¤ò¤·¤Æ¡¢¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¥ï¥¯¥Á¥óÀܼï¤Ø¤È¡¢¸þ¤«¤ï¤»¤ë¡£¡×¡Ö“Ces mutations du virus H1N1 doivent ½æStre prises tr½æQs au s½æPrieux“¡×¤è¤ê)

D225GÊÑ°Û¥¦¥¤¥ë¥¹¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤ì¤Þ¤Ç¤Î¥¦¥¯¥é¥¤¥Ê¡¢¥Î¥ë¥¦¥§¥¤¡¢¹á¹Á¤Ë³¤¤¤Æ¡¢¥Õ¥é¥ó¥¹¤Ç¤â¡¢Æ±ÍͤÎÊÑ°Û¥¦¥¤¥ë¥¹¤¬³Îǧ¤µ¤ì¤¿¡£

¥Õ¥é¥ó¥¹¤Ç¤ÎD225GÊÑ°Û¥¦¥¤¥ë¥¹¤òÍ­¤·¤Æ¤¤¤ë´µ¼Ô¤Ï¡¢Æó¿Í¤ª¤ê¡¢¤½¤Î¤¤¤º¤ì¤â½ÅÂ֤Ǥ¢¤ê¡¢¤½¤Î¤¦¤Á¤Î°ì¿Í¤Ë¤Ï¡¢¥¿¥ß¥Õ¥ëÂÑÀ­¤¬¸«¤é¤ì¤¿¤È¤¤¤¦¡£

¥Ö¥é¥¸¥ë¤Ç¤âƱ¼ï¤ÎÊÑ°Û¥¦¥¤¥ë¥¹¤¬¡¢¸«¤Ä¤«¤Ã¤Æ¤¤¤ë

»²¹Í
2009ǯ11·î26Æü¤ÎWHO¤Î¥Ð¡¼¥Á¥ã¥ëµ­¼Ô²ñ¸«¤Ç¤Î¥¦¥¤¥ë¥¹ÊѰۤ˴ؤ¹¤ëÉôʬȴ¿è

(Transcript of virtual press conference with Kristen Kelleher, Communications Officer for pandemic (H1N1) 2009, and Dr Keiji Fukuda, Special Adviser to the Director-General on Pandemic Influenza, World Health Organization 26 November 2009 )

Dr Keiji Fukuda:
Now the last point that I want to address before I throw it open to questions is that in the last several days we have also seen a lot of reports in the media about a mutation and this was specifically raised because it was Norway which recently reported seeing mutations in three patients who had severe disease.

Since then there have been additional reports of the same mutation being seen in viruses in a number of other countries, such as Brazil, China, Japan, Ukraine and the US [CORRECTION FOR ACCURACY: AND MEXICO].

The question is whether this mutation again suggests that there is a fundamental change going on in viruses out there or whether there is a turn for the worse in terms of the severity.

I think that the answer right now is that we are not sure.

I want to answer why we are not sure in a way which explains why more investigations are needed.

As you know these influenza viruses change frequently.

Their gene properties change because these are viruses which frequently undergo mutations and so mutations in and of themselves are not necessarily important and in fact, if every mutation was reported out there, it would be like reporting changes in the weather - saying that there is a temperature difference of one degree one hour and then an hour later, saying there is a temperature increase or decrease of one¡¡degree.

This kind of information does not really help anybody.

But, what we try to do when we see reports of mutations is to identify whether these mutations are leading to any kind of changes in the clinical picture - do they cause more severe disease or less severe disease and also we try to look at whether these viruses are increasing out there, suggesting that there may be a change in the epidemiology.

With this particular mutation we have seen that it is reported in people who have severe disease and we have also seen that it is also been reported in people who have milder disease.

Right now one of the questions is, is it really associated with severe disease more often.

The second point that though, is are these viruses becoming more common or are they relatively infrequent.

So again, this requires looking at more viruses over time to get a sense of whether there is a change in the overall prevalence or number of these viruses.

It is these kinds of investigations which require time and it is these kinds of questions which have to be answered before we can fully talk about the importance of one mutation or another mutation.

»²¹Í¡¡225¥Ý¥¸¥·¥ç¥ó¤Ç¤ÎÊÑ°Û°ìÍ÷

RPKVRDQEGRI,>A/Kansas/UR06-0068/2007(H1N1)
RPKVRGQAGRI,>A/Index/1977(H1N1)
RPKVRDQSGRM,>A/Denver/1957(H1N1)
RPKVRDQAGRM,>A/Index/early human
RPKVRDQAGRM,>A/Brevig Mission/1/1918(H1N1)
RPKVRGQAGRM,>A/Index/early swine
RPKVRGQAGRM,>A/swine/Jamesburg/1942(H1N1)
RPKVRGQAGRM,>A/New Jersey/1976(H1N1)
RPKVRDQEGRM,>A/******/index/2009/02/01
RPKVRGQEGRI,>A/Taiwan/01/1986///
RPKVRGQEGRI,>A/Beijing/262/1995///
RPKVRDQEGRI,>A/New Caledonia/20/1999///
RPKVRDQEGRI,>A/Solomon Islands/3/2006/08/21/
RPKVRDQEGRI,>A/Brisbane/59/2007/07/01/
RPKVREQAGRM,>A/swine/Germany/2/1981(H1N1)=1578
RPKVRDQAGR-,>A/******-match/1-2/07(H3N2)
RPKVRDQPGRM,>A/UK/1/1933(H1N1)
RPKVRDQAGRM,>A/Puerto Rico/8-1/1934(H1N1)
RPKVRGQEGRI,>A/Texas/36/1991(H1N1)
RPKVRNQEGRI,>A/Chile/1/1983(H1N1)

¡ÖOne of the D225G cases is a low reactor? ¡×¤è¤ê

»²¹Í
¡ÖWHO Confirms That The H1N1 Swine Flu Has Mutated In Ukraine – But That We Should Not Worry¡×

D225GÊÑ°Û´ØÏ¢¥Ó¥Ç¥ª



¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢2,950±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/25 Wednesday

¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 09:52:08

¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø

¤³¤Î¾ðÊó¤Ï11·î25Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ­¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ­»ö¤Ç¤Ï¡¢²¼µ­¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ­»ö½ç¤Ç¤¹¡£

D225GÊÑ°ÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ(11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ(11·î19Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)

£²£°£°£¹Ç¯£±£±·î£²£µÆü
¡¡
¥¦¥¯¥é¥¤¥Ê¤ä¥Î¥ë¥¦¥§¥¤¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎÊѰۤˤĤ¤¤Æ¤Ï¡¢Á°¤Î»ä¤Î¥Ö¥í¥°µ­»ö
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´¡×
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ¡×
¡Ö³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ¡×
¤Ê¤É¤Ç¾Ò²ð¤·¤¿¡£

¤³¤³¤Ë¤­¤Æ¡¢¹á¹Á¤Ç¤â¡¢¥Î¥ë¥¦¥§¥¤¤ÈƱ¤¸ÊÑ°Û¤ò»ý¤Ä¥¦¥¤¥ë¥¹¤¬³Îǧ¤µ¤ì¤¿¤È¤¤¤¦¡£

¤³¤³¤Ç¡¢¤Á¤ç¤Ã¤È¡¢À°Íý¤ò¤·¤Æ¤ª¤³¤¦¡£

ÊѰۤϡ¢£²£²£µ¥Ý¥¸¥·¥ç¥ó¤Ë¤ª¤±¤ëÊѰۤǤ¢¤ë¡£

¥¦¥¯¥é¥¤¥Ê¤Î¾ì¹ç

10¸¡ÂΤΤ¦¤Á¡¢4¸¡ÂΤˡ¢HA¤Ë¤ª¤¤¤Æ¡¢D225GÊÑ°Û¤ò¼¨¤·¤Æ¤¤¤¿¤È¤¤¤¦¡£

D225GÊÑ°Û¤òµ¯¤³¤·¤Æ¤¤¤ë¥¦¥¤¥ë¥¹Ì¾¤Ï²¼µ­¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/Lviv/N6/2009
A/Ternopil/N11/2009
A/Ternopil/N10/2009
A/Lviv/N2/2009

¤³¤Î¤¦¤Á¡¢1¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢¹¢¤«¤é¤Î¤â¤Î¤Ç¤¢¤ê¡¢3¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢ÇÙÁÈ¿¥¤«¤é¤Î¤â¤Î¤Ç¤¢¤Ã¤¿¡£

¥Î¥ë¥¦¥§¥¤¤Î¾ì¹ç

£µ·î¤«¤é£±£°·î¤Ë¤«¤±¤ÆºÎ¼è¤·¤¿¸¡ÂΤΤ¦¤Á¡¢¤¹¤Ù¤Æ¤¬£²£²£µ¥Ý¥¸¥·¥ç¥ó¤Ë¤ª¤±¤ëÊÑ°Û¤¬¸«¤é¤ì¤¿¡£

¤½¤Î¤¦¤Á¡¢£µ¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢D225EÊѰۤǤ¢¤Ã¤¿¡£

¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢²¼µ­¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/Norway/4023/2009
A/Norway/3478/2009
A/Norway/3059/2009
A/Norway/2690/2009
A/Norway/2674/2009

£±¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢¥ï¥¤¥ë¥É¡¦¥¿¥¤¥×¤È¤Îº®¹çʪ¤È¤ß¤é¤ì¤ëD225¤Ç¤¢¤ê¡¢D225GÊѰۤǤ¢¤Ã¤¿¡£

¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢²¼µ­¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/Norway/2924/2009

¹á¹Á¤Î¾ì¹ç

¥Î¥ë¥¦¥§¥¤¤ÈƱÍͤÎÊÑ°Û¤¬¸«¤é¤ì¤¿¤È¤ÎÊóÆ»¤À¤¬¡¢¶ñÂÎŪ¤Ê¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢È¯É½¤µ¤ì¤Æ¤¤¤Ê¤¤¡£

¤³¤Î¥µ¥¤¥È¡ØÕó²È¡§¹Ã·¿H1N1ή´¶ÚμïÉÂÆÇ ÃæÔ¢6·î½¢Öá⤸½¡Ù¤Ë¤è¤ë¤È¡¢ÊѰۤϡ¢D225GÊÑ°Û¤ÈD225EÊÑ°Û(H3¥Ù¡¼¥¹¤Ç225¤Ç¤¢¤ê¡¢H1¥Ù¡¼¥¹¤Ç222¤Ç¤¢¤ë¡£HA´ð°ø222°Ì氨´ð»À°ÌóÚÚΰÛ)¤Ç¤¢¤ê¡¢¤½¤Î°ìÎã¤Ï¡¢º£Ç¯6·î¤Ë¥¤¥®¥ê¥¹¤«¤é¤Îµ¢¹ñ¼Ô¤«¤é¸«¤Ä¤«¤Ã¤¿¤â¤Î¤Ç¡¢¤â¤¦°ìÎã¤Ï¡¢9·î¤ËÞ¶¹¾¾ÊÞ¶¹¾îвÊÂçÕܤÇȯ¸«¤µ¤ì¤¿¤â¤Î¤Ç¤¢¤ë¤È¤Î¤³¤È¤Ç¤¢¤ë¡£

¤Þ¤¿¡¢¤³¤Î¥µ¥¤¥È¤Ë¤è¤ì¤Ð¡¢¸½ºß¡¢Ãæ¹ñ¤Ç¤Ï¡¢8Îã¤Î225Úΰۤ¬¤¢¤ë¤È¤¤¤¦¡£

»²¹Í
¡ÖMutation detected in Hong Kong toddler ¡×
¹á¹Á¤Î¿·¤·¤¤H1N1ÊѼï¾ðÊó¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤Î¥µ¥¤¥È¤´»²¾È

¡Ö¹á¹Á±ÒÀ¸½ðº¬Ú¡挪°Ò¸øÉÛŪÚμïÉÂÆÇ»ñÎÁ¡¤Üý查³º½ð´Æ¬·ÏÅýÁ½¿Ê¹ÔŪ¹Ã·¿Î®´¶ÉÂÆÇÜëËÜŪ´ð°ø½øÎ󡤷ë²Ì⤸½ºß³º½ð¿Ê¹ÔŪ123¸Ä´ð°ø½øÎ󸦵桤¶ÃæÍ­°ì¸ÄÉÂÆÇÜëËÜÁ½½Ð¸½ÚμÉÂÆÇŪ´ð°ø½øÎóËòçÐ挪°Ò½Ð¸½ÅªÃ×Ì¿ÚμïÉÂÆÇÁêƱ¡£ ¡×
(¹á¹Á±ÒÀ¸½ð´ÆÆÄ·ÏÅý¤Ï123¸Ä¤ÎH1N1·¿¥¤¥ó¥Õ¥ë¤ÎDNAÇÛÎó¤ËÂФ¹¤ë¸¦µæ¤ò¹Ô¤¤¡¢ÃË»ù¤Î¥µ¥ó¥×¥ë¤¬¥Î¥ë¥¦¥§¡¼¤Çή¹Ô¤·¤Æ¤¤¤ëÊÑ°Û¥¦¥¤¥ë¥¹¤ÈƱ¤¸¤Ç¤¢¤ë¤³¤È¤òȯ¸«¤·¤¿¡£Æ±¥¦¥¤¥ë¥¹¤Ï¡¢¥¿¥ß¥Õ¥ë¤ä¥ì¥ì¥ó¥¶¤ËÂФ·¡¢¹³ÌôÀ­¤Ï¸½¤ì¤Æ¤¤¤Ê¤¤¤È¤¤¤¦¡£)
¡ÖËܹÁ1歲ÃËƸÈïñä½Ð´¶À÷Úμï¹ÃήÉÂÆÇ(çÐ挪°ÒÉÂÆÇÁêƱ)¡¤Á½ºß7·îÄìÆþ½»º»ÅÄ°Ò¼¤»Ûîб¡¡£»ñÎÁÔ¦ÊÒ¡×

¼õÍÆÂÎÊѰۤˤĤ¤¤Æ

¥Ñ¥¿¡¼¥óǧ¼±¼õÍÆÂÎÅÁã¤ò¾ã³²¤¹¤ëÊÑ°Û¤¬¤¢¤Ã¤¿¤«¤É¤¦¤«¤¬¡¢ºÇÂç¤Î¥Ý¥¤¥ó¥È¤Î¤è¤¦¤Ç¤¢¤ë¡£

¤¹¤Ê¤ï¤Á¡¢¤³¤Î¤³¤È¤Ï¡¢¤Ê¤¼¡¢¥¦¥¯¥é¥¤¥Ê¤Ç¡¢¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ç»àË´¤·¤¿´µ¼Ô¤ÎÇÙÁÈ¿¥¤ËÊÑ°Û¤¬¸«¤é¤ì¤¿¤Î¤«¡¢¤È¤¤¤¦¤³¤È¤Ë´Ø·¸¤·¤Æ¤¯¤ë¡£

¤¹¤Ù¤Î¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ºÙ˦¤Ë¼è¤êÉÕ¤¯¤¿¤á¤Ë¡¢¥·¥¢¥ë»À¤òɬÍפȤ¹¤ë¡£

¥·¥¢¥ë»À¤Ë¤Ï¡¢¤¤¤í¤¤¤í¤Ê²½³ØŪ¤Ë¤³¤È¤Ê¤ë¼ïÎब¤¢¤ê¡¢¤½¤ì¤Ë¤è¤Ã¤Æ¡¢¥¦¥¤¥ë¥¹¤È¤Î¿ÆÏÂÀ­¤¬¤³¤È¤Ê¤ë¡£

Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á 2,3 ·ë¹ç¤·¤¿¤â¤Î¡ÊSA¦Á2,3Gal¡Ë¤òǧ¼±¤·¡¢

¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¼ç¤È¤·¤Æ¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á2,6·ë¹ç¤·¤¿¤â¤Î (SA¦Á2,6Gal )¤òǧ¼±¤¹¤ë¡£

¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¡¢¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¤Ç¤Ï°Û¤Ê¤ê¡¢

¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¡¢¥Ò¥È¤Î¾åÉôµ¤Æ»¤ÎÉ¡Ç´Ëì¡¢ÉûÉ¡¹Ð¡¢°öƬ¡¢µ¤´É¡¤µ¤´É»Ù¤Î¾åÈéºÙ˦¤Ë¤·¤«¤Ê¤¤¤¬¡¢

Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¥Ò¥È¤Î¸ÆµÛ´ï¤Î¿¼Éô¡Ê¸ÆµÛºÙµ¤´É»Ù¤ÈÇÙ˦ºÙ˦¤Î°ìÉô¤Ç¤¢¤ê¡¢¸ÆµÛºÙµ¤´É»Ù¤È˦¤ÈII·¿ÇÙ˦¾åÈéºÙ˦¤È¤Î´Ö¤Î·ë¹çÉô¤Ç¤¢¤ëÈóÀþÌÓµ¤Æ»ºÙ˦-nonciliated bronchiolar cells-¤Ë¤¢¤ë¡£¡Ë¤Ë¡¢Â¿¤¯Â¸ºß¤¹¤ë¡£

¥¦¥¤¥ë¥¹¤Î¡Ö¼õÍÆÂηë¹ç¥É¥á¥¤¥ó¡×(receptor-binding domain )(RBD)¤Ç¤ÎÊÑ°Û¤¬¡¢¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó¤ò¥Ò¥È¼õÍÆÂΤ˷ë¹ç¤·°×¤¯¤·¡¢¿Í¤Ø¤Î´¶À÷¤ÎÍưפµ¤ò·èÄê¤Å¤±¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£

¤³¤Îreceptor-binding site(RBD)¤Ï¡¢£È£Á¤Ë¤è¤Ã¤Æamino acids position ¤Î²¿ÈÖÌܤ˰ÌÃÖ¤¹¤ë¤«¤¬°Û¤Ê¤Ã¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£

¤³¤³¤Ç¡¢¥Ñ¥¿¡¼¥óǧ¼±¼õÍÆÂÎÅÁã¤ò¾ã³²¤¹¤ëÊÑ°Û¤¬¤¢¤ì¤Ð¡¢ÇÙÁÈ¿¥¤Ë¤ª¤±¤ë¥ì¥»¥×¥¿¡¼¤¬¡¢¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤òǧ¼±¡ÊSA¦Á2,3Gal¡Ë¤¹¤ë¤³¤È¤â¤¢¤ê¤¦¤ë¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£

¤Ä¤Þ¤ê¡¢¥Ò¥È¤«¤éʬΥ¤µ¤ì¤¿H1N1¥¦¥¤¥ë¥¹¤¬¡¢¥Ò¥È¤ª¤è¤ÓÄ»¤ÎξÊý¤Î¼õÍÆÂΤ˷ë¹ç¤Ç¤­¤ëÂÎÀ©¤¬¡¢ÊѰۤˤè¤Ã¤Æ¡¢À°¤¦¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£

¤¢¤ë¤¤¤Ï¡¢Ç§¼±¤ÎÂоݤ¬¡¢Ä»¤ÎSA¦Á2,3Gal¤È¥Ò¥È¤ÎSA¦Á2,6Gal¤È¤Îº®¹çʪ¤Ç¤¢¤Ã¤¿¾ì¹ç¤â¡¢ÇÙÁÈ¿¥¤Ç¡¢SA¦Á2,3Gal°Ê³°¤Îº®¹çʪ¤òǧ¼±¤¹¤ë¤³¤È¤â¤¢¤ê¤¦¤ë¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£

¥¦¥¤¥ë¥¹¤Ë¹¥¤Þ¤ì¤ë¥·¥¢¥ë»À¤ò¥³¥ó¥È¥í¡¼¥ë¤¹¤ë¤Î¤Ï¡¢¥Ý¥¸¥·¥ç¥ó190¤È¥Ý¥¸¥·¥ç¥ó225¤Ç¤ÎÊѰۤǤ¢¤ë¤È¤¤¤ï¤ì¤ë¡£

¤½¤³¤Ç¡¢D225GÊÑ°Û¤Þ¤¿¤ÏD225EÊÑ°Û¤¬¡¢¼õÍÆÂÎÊѰۤˤª¤¤¤Æ¡¢Ä»¤ÎSA¦Á2,3Gal¤È¥Ò¥È¤ÎSA¦Á2,6Gal¤È¤Î¤É¤Á¤é¤Îǧ¼±¤Ë±Æ¶Á¤òµÚ¤Ü¤¹¤«¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¤Î¤À¤¬¡£

D225GÊѰۤϡ¢Ä»¤ÎSA¦Á2,3Gal¤È¥Ò¥È¤ÎSA¦Á2,6Gal¤È¤ò¤È¤â¤Ë¥¿¡¼¥²¥Ã¥È¤Ë¤·¤¦¤ë¡¢¤È¤µ¤ì¤ë¡£

¤³¤ì¤é¤Ë¤Ä¤¤¤Æ¤Ï¡¢»ä¤Î°ÊÁ°¤Î¥Ö¥í¥°µ­»ö
¡Ö¿Í´Ö¤Î¾åµ¤Æ»¤¬¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¤Î¾ì½ê¡×¤È¤¤¤¦Àµ·î°ÊÍèÏÃÂê¤ÎÏÀʸ¡×
¡ÖH5N1¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î¥Ò¥È·¿¼õÍÆÂΤؤηë¹ç¤ò²Äǽ¤Ë¤¹¤ë¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó¤ÎÊÑ°Û¡×
¡ÖHaemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors¡×
¤Ê¤É¤â¤´»²¾È

¤Ê¤¼¡¢D225GÊÑ°Û¤¬ÇÙ¤òľ·â¤¹¤ë¤Î¤«?

¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤¬Ç§¼±¤¹¤ëSA¦Á2,3Gal¼õÍÆÂΤ¬II·¿ÇÙ˦¾åÈéºÙ˦( Type II Alveolar Epithelial Cells )¤Î¾å¤Ë¤¢¤ë¤¿¤á¤È¤¤¤ï¤ì¤Æ¤¤¤ë¡£

¤³¤ÎII·¿ÇÙ˦¾åÈéºÙ˦¤Ï¡¢¥µ¥¤¥È¥«¥¤¥ó¤Îȯ¸½¤ò´Þ¤àÌȱÖËɸæ¤È¤È¤â¤Ë¡¢ÇÙ¤ÎɽÌÌÄ¥ÎϤòÄ´À°¤¹¤ëÌò³ä¤òô¤Ã¤Æ¤¤¤ë¡£

D225GÊѰۤˤè¤Ã¤Æ¡¢H1N1¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤¬¡¢ËÜÍè¤Ï¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤¬Ç§¼±¤¹¤ëSA¦Á2,3Gal¼õÍÆÂΤòǧ¼±¤·¤Æ¤·¤Þ¤¦¤³¤È¤Ë¤è¤Ã¤Æ¡¢II·¿ÇÙ˦¾åÈéºÙ˦¤Ë¤È¤ê¤Ä¤­¡¢¥µ¥¤¥È¥«¥¤¥ó¤Îȯ¸½¤òÂ¥¤¹¡¢¤È¤¤¤¦¤³¤È¤Î¤è¤¦¤À¡£

¤·¤«¤·¡¢°ìÊý¡¢°Ê²¼¤Î¤è¤¦¤ÊÀâ¤â¤¢¤ë¤è¤¦¤À¡£

¤¹¤Ê¤ï¤Á¡¢D225GÊѰۤϡ¢´¶À÷¤òÁ˳²¤¹¤ëÊѰۤǤ⤢¤ë¤Î¤Ç¡¢Áý¿£¤Ï¤È¤Þ¤é¤Ê¤¤¤¬¡¢´¶À÷¤Ï°ìÄê¤Î²Õ½ê¤Ç¤È¤É¤Þ¤ë¤È¤¤¤¦¤³¤È¤Ç¡¢¥¦¥¯¥é¥¤¥Ê¤Ê¤É¤Ç¡¢ÇÙÁÈ¿¥¤Ê¤É°ìÄê¤ÎÉôʬ¤Î¤ß¤¬¥¦¥¤¥ë¥¹¤Ë¤ª¤«¤µ¤ì¤Æ¤¤¤ë¤Î¤Ç¤Ï¤Ê¤¤¤Î¤«¡¢¤È¤¤¤¦¸«Êý¤À¡£
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ÖThe D225G change in 2009 H1N1 influenza virus is not a concern¡×¤ò¤´»²¾È

»²¹Í¡Ö1918 RBD D225G in Lung Cases in the United States¡×
¡ÖCytokine Regulation in Type II Alveolar Epithelial Cells as the Mechanism for Interstitial Pneumonia by Gefitinib¡×

¥¹¥Ú¥¤¥óÉ÷¼Ù¤ÈD225GÊѰۤȤδط¸

¾åµ­¤ÎD225GÊÑ°Û¤Þ¤¿¤ÏD225EÊѰۤϡ¢£±£¹£±£¸Ç¯¤È£±£¹£±£¹Ç¯¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤Ë¤ª¤¤¤Æ¤â¡¢¸«¤é¤ì¤¿ÊѰۤǤ¢¤ë¡£

¤½¤Î¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢¼¡¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/New York/1/1918
A/London/1/1919

ÊÑ°Û¥¦¥¤¥ë¥¹¤Ç¤Ê¤¤A/South Carolina/1/18 ¤Ï¡¢alpha(2,3)(Ä»¥¦¥¤¥ë¥¹Ç§¼±)¤ò¹¥¤ß¡¢A/New York/1/1918 ¤Ï¡¢alpha(2,3)(Ä»¥¦¥¤¥ë¥¹Ç§¼±) ¤È¡¡alpha(2,6)(¥Ò¥È¡¦¥¦¥¤¥ë¥¹Ç§¼±)¡¡¤È¤ÎξÊý¤ò¹¥¤ó¤À¡£

A/South Carolina/1/18 ¤Ï¡¢¥Ý¥¸¥·¥ç¥ó225¤Ë¤ª¤¤¤Æ¡¢ÊÑ°Û¤·¤Æ¤ª¤é¤ºD¤Ç¤¢¤Ã¤¿¡£

A/New York/1/1918 ¤Ï¡¢¥Ý¥¸¥·¥ç¥ó225¤Ë¤ª¤¤¤Æ¡¢ÊÑ°Û¤·¤Æ¤ª¤ê¡¢G¤Ç¤¢¤Ã¤¿¡£

A/New York/1/1918 ¤Ï¡¢¥Ý¥¸¥·¥ç¥ó190¤Ë¤ª¤¤¤Æ¡¢D¤«¤éE¤Ë¡¢D190EÊÑ°Û¤·¤Æ¤¤¤¿¡£

¤³¤ÎD190EÊѰۤϡ¢alpha(2,3)(Ä»¥¦¥¤¥ë¥¹Ç§¼±)¤È¤Î¥Ð¥¤¥ó¥É¤ò¹¥¤à¡£

¤³¤ÎD190EÊÑ°Û¤ÈD225GÊѰۤȤ¬¡¢Æ±»þ¤Ëµ¯¤³¤ë¤È¡¢¤½¤Î¥¦¥¤¥ë¥¹¤Î¦Á(2,6)¤Ø¤Î¼è¤êÉÕ¤­(¥Ð¥¤¥ó¥Ç¥£¥ó¥°)¤Ï¡¢Ãø¤·¤¯¼å¤Þ¤ë¤È¤¤¤¦¡£

1918¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤òÍѤ¤¤Æ¤Î¡¢SC18¤È¸Æ¤Ð¤ì¤ë¡¢1918Âçή¹Ô¤Î¸¶°ø¥¦¥¤¥ë¥¹¤È¡¢SC18¤È¤Ï1¤Ä¤À¤±¥¢¥ß¥Î»À¤¬°Û¤Ê¤ëNY18¤È¡¢2¸Ä¤Î¥¢¥ß¥Î»À¤¬°ã¤¦AV18¤È¸Æ¤Ð¤ì¤ë¥¦¥¤¥ë¥¹¤È¤òÈæ³Ó¤·¤¿·ë²Ì¡¢¤³¤Î¤¦¤ÁAV18¤È¸Æ¤Ð¤ì¤ë¥¦¥¤¥ë¥¹¤Ï¡¢D190EÊÑ°Û¤ÈD225GÊѰۤȤòƱ»þ¤Ëµ¯¤³¤·¤Æ¤ª¤ê¡¢¤³¤ÎAV18¥¦¥¤¥ë¥¹¤Ï¡¢¦Á(2,6)¤Ø¤Î¼è¤êÉÕ¤­(¥Ð¥¤¥ó¥Ç¥£¥ó¥°)¤¬¤Þ¤Ã¤¿¤¯¤Ê¤«¤Ã¤¿¤È¤¤¤¦¡£
»²¹Í¡ÖMIT explains spread of 1918 flu pandemic¡×

CDC¤ÎNancy J. Cox »á¤ò¤Ï¤¸¤á¤È¤¹¤ë59¿Í¤«¤é¤Ê¤ë¸¦µæ¥Á¡¼¥à¤ÎH1N1 ¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î°äÅÁ»ÒʬÀϤˤè¤ì¤Ð¡¢8¤Ä¤Î¥»¥°¥á¥ó¥È¤Î¤¦¤Á¡¢¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó(H)¤ò´Þ¤à3¤Ä¤Î°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ï¡¢1918ǯ¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤ÎH1N1¤ËͳÍ褹¤ë¤â¤Î¤Ç¤¢¤ê¡¢¤½¤Î¸å¡¢¤º¤Ã¤ÈÆڤ˸ºß¤·¤Æ¤¤¤¿¤â¤Î¤Ç¤¢¤ë¤¬¡¢¤½¤Î´Ö¤Ë¤ª¤¤¤Æ¤â¡¢ÊѰۤϤ·¤Æ¤¤¤Ê¤«¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£

°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ç¤Ï¡¢¥Ý¥ê¥á¥é¡¼¥¼B(PB)°äÅÁ»Ò¤Ï¥Ò¥ÈͳÍ衢¾¤ÎÆó¤Ä¤ÏĻͳÍè¤Ç¤¢¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£

¤Þ¤¿¡¢1918ǯ¤ÎH1N1¤ÈH5N1¤È¤Ï¡¢ÆÇÀ­¤¬¤¢¤ë¤³¤È¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤ò¡¢Æ±¤¸NS1¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤ÆÍ­¤·¤Æ¤¤¤ë¤¬¡¢º£²ó¤Î¿·H1N1¤Ï¡¢¤½¤¦¤Ç¤Ï¤Ê¤¤¤È¤¤¤¦¡£

´¶À÷À­¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤Æ¤â¡¢º£²ó¤Î¿·H1N1¤Ï¡¢1918ǯ¤ÎH1N1¤Ë¤¢¤Ã¤¿¤â¤Î¤ò¼º¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¡£

»²¹Í1.
¤³¤ì¤Þ¤ÇD225GÊÑ°Û¤ò¤ß¤»¤¿¥¦¥¤¥ë¥¹Ì¾°ìÍ÷
(¥¦¥¯¥é¥¤¥Ê¤È¥Î¥ë¥¦¥§¥¤¤Îʬ¤ò½ü¤¯)

01¡¡A/******/index/2009/02/01 (A/swine-flu/index/2009-02-01(H1N1))
02¡¡A/Hiroshima/201/2009/06/17
03¡¡A/Georgia/01/2009/04/27
04¡¡A/Zhejiang-Yiwu/11/2009/09/06
05¡¡A/Zhejiang/DTID-ZJU03/2009/09/07
06¡¡A/Zhejiang/DTID-ZJU02/2009/09/07
07¡¡A/Sao Paulo/53206/2009/07/19
08¡¡A/Sao Paulo/53225/2009/08/01
09¡¡A/New York/04/2009/04/
10¡¡A/Catalonia/NS1706/2009/07/29
11¡¡A/Mexico/InDRE4114/2009//
12¡¡A/Texas/11/2009/04/23
13¡¡A/Texas/05/2009/04/15
14¡¡A/Mexico/3955/2009/04/02
15¡¡A/Cancun-NY/Index/2009/04/15

»²¹Í2.
¤³¤ì¤Þ¤ÇD225EÊÑ°Û¤ò¤ß¤»¤¿¥¦¥¤¥ë¥¹Ì¾°ìÍ÷

¡ÖRhiza Labs FluTracker Forum¡×¤«¤é

A/Norway/4023/2009(H1N1)¡¡¡¡¡¡
A/Norway/3478/2009(H1N1)
A/Norway/3059/2009(H1N1)
A/Norway/2690/2009(H1N1)
A/Norway/2674/2009(H1N1)
(A/Catalonia/S1761/2009(H1N1)
A/Catalonia/S1758/2009(H1N1)
A/Catalonia/S1748/2009(H1N1)
A/Catalonia/S1698/2009(H1N1).
A/Catalonia/S1674/2009(H1N1)
A/Catalonia/S1672/2009(H1N1)
A/Serbia/3547/2009(H1N1)
A/Catalonia/S1641/2009(H1N1)
A/Catalonia/S1637/2009(H1N1)
A/Catalonia/S1632/2009(H1N1)
A/Catalonia/S1606/2009(H1N1)
A/Catalonia/S1605/2009(H1N1)
A/Catalonia/S1604/2009(H1N1)
A/Nagasaki/HA-44/2009(H1N1)
A/Catalonia/S1592/2009(H1N1)
A/Catalonia/S1587/2009(H1N1)
A/Catalonia/S1545/2009(H1N1)
A/Catalonia/S1479/2009(H1N1)
A/Catalonia/S1478/2009(H1N1)
A/Catalonia/S1436/2009(H1N1)
A/Catalonia/S1379/2009(H1N1)
A/Catalonia/S1369/2009(H1N1)
A/Catalonia/S1350/2009(H1N1)
A/Catalonia/S1333/2009(H1N1)
A/Catalonia/S1331/2009(H1N1)
A/Catalonia/S1304/2009(H1N1)
A/Catalonia/S1300/2009(H1N1)
A/Catalonia/S1286/2009(H1N1)
A/Catalonia/S1273/2009(H1N1)
A/Catalonia/S1272/2009(H1N1)
A/Catalonia/S1269/2009(H1N1)
A/Catalonia/S1265/2009(H1N1)
A/Catalonia/S1260/2009(H1N1)
A/Catalonia/S1254/2009(H1N1)
A/Catalonia/S1249/2009(H1N1)
A/Catalonia/S1248/2009(H1N1)
A/Catalonia/S1237/2009(H1N1)
A/Catalonia/S1236/2009(H1N1)
A/Catalonia/S1227/2009(H1N1)
A/Catalonia/S1222/2009(H1N1)
A/Catalonia/S1215/2009(H1N1)
A/Catalonia/S1209/2009(H1N1)
A/Catalonia/S1205/2009(H1N1)
A/Catalonia/S1199/2009(H1N1)
A/Catalonia/S1187/2009(H1N1
A/Catalonia/S1183/2009(H1N1)
A/Catalonia/S1182/2009(H1N1)
A/Catalonia/S1165/2009(H1N1)
A/Catalonia/S1161/2009(H1N1)
A/Catalonia/S1120/2009(H1N1)
A/Almati/01/2009(H1N1)
A/Changsha/78/2009(H1N1)
A/California/25/2009(H1N1)
A/Milan/83/2009(H1N1)
A/Milan/80/2009(H1N1)
A/Ancona/05/2009(H1N1)
A/Catalonia/378/2009(H1N1)
A/Italy/172/2009(H1N1)
A/Sapporo/1/2009(H1N1)
A/Catalonia/387/2009(H1N1)
A/Hong Kong/2369/2009(H1N1)
A/Athens/893/2009(H1N1)
A/Paris/2591/2009(H1N1)
A/New Jersey/01/2009(H1N1)

»²¹Í3.¥Ý¥¸¥·¥ç¥ó225¤Ç¤ÎÊÑ°Û

D225N
¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¤ä¥Ë¥å¡¼¥è¡¼¥¯¤Ç¸«¤é¤ì¤¿ÊÑ°Û

D225G
¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¡¢Ãæ¹ñ¡¦Zhejiang¡¢ÆüËÜ¡¦¹­Åç¡¢¥¢¥á¥ê¥«¡¦¥Æ¥­¥µ¥¹¡¢¥¢¥á¥ê¥«¡¦¥¸¥ç¡¼¥¸¥¢¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥è¡¼¥¯¡¢¥á¥­¥·¥³¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¤Ç¸«¤é¤ì¤¿ÊÑ°Û

D225E
ÆüËÜ¡¦Ä¹ºê¡¢ÆüËÜ¡¦»¥ËÚ¡¢Ãæ¹ñ¡¦¹á¹Á¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥¸¥ã¡¼¥¸¡¼¡¢¥¢¥á¥ê¥«¡¦¥«¥ê¥Õ¥©¥ë¥Ë¥¢¡¢¥Õ¥é¥ó¥¹¡¦¥Ñ¥ê¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¡¢ ¥«¥¶¥Õ¥¹¥¿¥ó¡¦¥¢¥ë¥Þ¥È¥¤¡¢Ãæ¹ñ¡¦Ä¹º»¡¢¥¤¥¿¥ê¥¢¡¦¥ß¥é¥Î¡¢¥¤¥¿¥ê¥¢¡¦¥¢¥ó¥³¡¼¥Ê¡¢¥®¥ê¥·¥ã¡¦¥¢¥Æ¥Í¡¢¤Ç¸«¤é¤ì¤¿ÊÑ°Û

¤½¤Î¾»²¹Í¥µ¥¤¥È
¡ÖRe: Sequences at Genbank! ¡×
¡Ö225G Preliminary Worldwide Tracking & Evaluation ¡×

H1N1ÊÑ°Û¤òÅÁ¤¨¤ëÃæ¹ñ¤Î¥Æ¥ì¥Ó¡ÖH1N1±Ö¾ðÁî¹çÊóÆ» - ¸áÌëºÇÁ°Àþ 20091122¡×


¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/23 Monday

¥«¥Ê¥À¤Ç»ÈÍÑÃæ»ß¤È¤Ê¤Ã¤¿¥ï¥¯¥Á¥ó¤Ë¤Ä¤¤¤Æ¤Î¾ÜºÙ¾ðÊó

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 10:04:33

2009ǯ11·î23Æü
¡¡
null¾ðÊ󤬺øÁ¤Æ¤¤¤ë¤è¤¦¤Ê¤Î¤Ç¡¢¤³¤³¤Ç¡¢¤Á¤ç¤Ã¤ÈÀ°Íý¤·¤Æ¤ß¤Þ¤·¤ç¤¦¤Í¡£

¥«¥Ê¥À¤Î±ÒÀ¸Åö¶É¤Ï11·î£²£²Æü¤Þ¤Ç¤Ë¡¢±Ñ°åÌôÉÊÂç¼ê¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¤¬À½Â¤¤·¤¿¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Î¥ï¥¯¥Á¥ó£±£·Ëü²óʬ¤Î»ÈÍѤòÃæ»ß¤¹¤ë¤³¤È¤ò·è¤á¤Þ¤·¤¿¡£

¤½¤ÎÍýͳ¤È¤·¤Æ¡¢Àܼï¸å¤ËÄ̾ï¤è¤ê¤â¹â¤¤ÈæΨ¤Ç½Å¤¤¥¢¥ì¥ë¥®¡¼²á¾êÈ¿±þ(¥¢¥Ê¥Õ¥£¥é¥­¥·¡¼¥·¥ç¥Ã¥¯)¤¬È¯À¸¤·¤¿¤¿¤á¤Ç¤¹¡£

¤È¤¯¤Ë¡¢¥«¥Ê¥ÀÃæÉô¤Î¥Þ¥Ë¥È¥Ð½£¤Ç¡¢¥°¥é¥¯¥½À½¤Î°ìÄêÎ̤Υ說¥Á¥ó¤Ë¤Ä¤¤¤Æ¡¢Ä̾¡Á£²Îã¤Ë¤È¤É¤Þ¤ë½Å¤¤ÉûºîÍѤ¬£¶ÎãȯÀ¸¤·¤¿¤È¤Î¤³¤È¤Ç¤¹¡£

¥«¥Ê¥ÀÀ¯Éܤ¬»ÈÍÑÃæ»ß¤òµá¤á¤¿¤Î¤Ï¡¢¼¡¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£

À½ÉÊ̾¡ÖArepanrix¡×

À½Â¤¥í¥Ã¥ÈÈÖ¹æ¡ÖA80CA007A¡×

¥ê¥³¡¼¥ëÂоݿôÎÌ¡Ö172,000Éþ¡×

½Ð²ÙÀè
British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Prince Edward Island

ÉûÈ¿±þÊó¹ð
11·î7Æü»þÅÀ¤Ç660Ëü²óʬ¶¡µë¡¢¤¦¤Á¡¢ÉûÈ¿±þÊó¹ð634Îã¡¢¤¦¤Á½Å¾ÉÎã36¡¢¤¦¤Á»àË´4Îã

¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Î³µÍ×

¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Ï¡¢¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼ÒÀ½¤Î¥¢¥¸¥å¥Ð¥ó¥È(AS03)Æþ¤ê¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£

¥¦¥¤¥ë¥¹¤ÎÇÝÍܤϡ¢È¯°é·ÜÍñÇÝÍÜË¡(embryonated egg culture)¤Ë¤è¤Ä¤Æ¤¤¤Þ¤¹¡£

¥¢¥¸¥å¥Ð¥ó¥ÈAS03¤Ï¡¢¥¹¥¯¥ï¥ì¥ó¤ò»ÈÍѤ·¤Æ¤¤¤ë¤¿¤á¡¢¥¢¥á¥ê¥«¤Î¥°¥é¥¯¥½¤Î¥ï¥¯¥Á¥ó¤Ç¤Ï»È¤ï¤ì¤Æ¤¤¤Þ¤»¤ó¡£

¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Ï¥«¥Ê¥À¡¦¥Ð¡¼¥¸¥ç¥ó¤Ç¤Î¾¦ÉÊ̾¤Ç¤¢¤ê¡¢¤³¤ì¤Ï¡¢Æ±¼Ò¤Î¡ÖPandemrix ¡×¤È¼Â¼Á¡¢Æ±¤¸¤â¤Î¤Ç¤¹¡£
»²¾È¡ÖPademrix and Arepanrix adjuvanted vaccines, made by GSK¡×

¤½¤Î¡ÖPandemrix ¡×¤Ï¡¢º£²óÆüËܤ¬Í¢Æþ¤Î¥°¥é¥¯¥½¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£

¡Ö¥Ñ¥ó¥Ç¥à¥ê¥¯¥¹¡×(Pandemrix)¤Ï¡¢¥â¥Ã¥¯¥¢¥Ã¥×(mock-up)¥ï¥¯¥Á¥ó¤Ç¤¹¡£
ÂоݤȤ¹¤ë¥¦¥¤¥ë¥¹³ô¤¬ÆÃÄꤵ¤ì¤Æ¤¤¤Ê¤¤Ãʳ¬¤Ç¡¢¥â¥Ç¥ë¥¦¥¤¥ë¥¹¤òÍѤ¤¤ÆºîÀ½¤µ¤ì¤¿¥ï¥¯¥Á¥ó¤Ç¡¢À½Â¤¾µÇ§¤Ï¤³¤ÎÃʳ¬¤ÇÆÀ¤Æ¤¤¤Þ¤¹¡£
Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹H5N1Âбþ¥ï¥¯¥Á¥ó¤È¤·¤Æ³«È¯¤µ¤ì¤¿¥ï¥¯¥Á¥ó¤Î¥â¥Ç¥ë¥¦¥¤¥ë¥¹¤ò¡¢A/Vietnam/1194/2004(H5N1)¤«¤éA/California/7/2009 (H1N1)¤ËÆþ¤ìÂؤ¨¤Æ¡¢À½Â¤¤·¤Æ¤¤¤ë¤â¤Î¤Ç¤¹¡£

¥«¥Ê¥À¤Î¡ÖArepanrix¡×¤âÆüËܤØÍ¢Æþ¤Î¡ÖPandemrix¡×¤â¡¢²¼µ­¤Î¥Ó¥Ç¥ª¤Ë¤¢¤ê¤Þ¤¹¤è¤¦¤Ë¡¢Æó¤Ä¤ÎÍÆ´ï¤ÈÃí¼Í´ï¤¬¥ï¥ó¥»¥Ã¥È¤Ë¤Ê¤Ã¤¿¤â¤Î¤Ç¤¹¡£
1.¥µ¥¹¥Ú¥ó¥·¥ç¥ó(Suspension)-¿ÉþÍÑÍÆ´ï¤Ë¥¢¥ó¥Á¥²¥ó(antigen)¤¬Æþ¤Ã¤Æ¤¤¤Þ¤¹¡£
2.¥¨¥Þ¥ë¥¸¥ç¥ó(Emulsion)-¥¢¥¸¥å¥Ð¥ó¥È(adjuvant)¤¬Æþ¤Ã¤Æ¤¤¤Þ¤¹¡£

¤³¤Î1¤È2¤ò¡¢¥ß¥Ã¥¯¥¹¤·¤Æ»È¤¤¤Þ¤¹¡£
¤¿¤À¡¢º®¹ç¤¹¤ëÁ°¤Ë¡¢Æó¤Ä¤¬¡¢Éô²°¤Î²¹Å٤ˤʤé¤Ê¤±¤ì¤Ð¤¤¤±¤Þ¤»¤ó¡£
»ÈÍÑÊýË¡¤Î¾ÜºÙ¤Ï¡¢¤³¤Î¥µ¥¤¥È¡ÖPandemrix suspension and emulsion for emulsion for injection¡×¤ò¤´Í÷¤¯¤À¤µ¤¤¡£

¤³¤ì¤é¤Î¤³¤È¤«¤é¡¢¤³¤ì¤é¤Î¥ï¥¯¥Á¥ó¤Ï´ÉÍý¤¬Æñ¤·¤¤¤È¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

¡ÖArepanrix¡×¤Î¥Ñ¥Ã¥±¡¼¥¸¤Ë¤Ï¡¢¡ÖBubble Wrap¡×¤È¡ÖShoe Box¡×¤È¤ÎÆó¼ïÎब¤¢¤ê¤Þ¤¹¡£

¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Ï¡¢»°Àé¿Í°Ê¾å¤Î¼£¸³¤ò·Ð¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤Æ¤Þ¤¹¤¬¡¢¤½¤ì¤¬¡¢H5N1¤Î¥â¥Ã¥¯¥¢¥Ã¥×¥ï¥¯¥Á¥ó¤ÎÁ°Ãʳ¬¤Ç¤Î¼£¸³¤ò´Þ¤ó¤Ç¤¤¤ë¤Î¤«¤¬ÌÀ¤é¤«¤Ç¤¢¤ê¤Þ¤»¤ó¡£¡£

¥«¥Ê¥À¤Ç¤Ï¡¢À¸¸å6¥ö·î¤«¤é3ºÐ°Ê²¼¤ÎÍÄ»ù¤Ë¤Ä¤¤¤Æ¤Ï¡¢Æó²óÀܼ»°ºÐ¤«¤é10ºÐ°Ê²¼¤Î»Ò¶¡¤ËÂФ·¤Æ¤Ï·ò¹¯¾õÂ֤˱þ¤¸¤Æ¡¢Æó²óÀܼ·ò¹¯¤Ê»°ºÐ¤«¤é10ºÐ°Ê²¼¤Î»Ò¶¡¤ËÂФ·¤Æ¤Ï¡¢°ì²óÀܼï¤ò¿ä¾©¤·¤Æ¤¤¤Þ¤¹¡£

¤·¤«¤·¡¢Arepanrix¤Ë¤Ä¤¤¤Æ¤Ï¡¢60ºÐ°Ê¾å¡¢10ºÐ¤«¤é17ºÐ¤Þ¤Ç¡¢À¸¸å6¥ö·î¤«¤é35¥ö·î¤Þ¤Ç¡¢¤³¤Î¤¤¤º¤ì¤ÎÀ¤Âå¤Ë¤Ä¤¤¤Æ¤Î clinical data¤¬ÌÀ¤é¤«¤Ë¤µ¤ì¤Æ¤¤¤Þ¤»¤ó¡£

¥¢¥Ê¥Õ¥£¥é¥­¥·¡¼¥·¥ç¥Ã¥¯(anaphylactic shock )¤Î¸¶°ø¤È¤·¤Æ¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥È(AS03)¤Ë´Þ¤Þ¤ì¤Æ¤¤¤ë³¦Ì̳èÀ­ºÞ¤Ç¤¢¤ëpolysorbate 80(Tween80)¤¬¸¶°ø¤È¤Î¸«Êý¤¬Í­ÎϤΤ褦¤Ç¤¹¡£
»²¹Í¡ÖPolysorbate 80 in medical products and nonimmunologic anaphylactoid reactions.
Coors EA, Seybold H, Merk HF, Mahler V
.¡×

¥«¥Ê¥À¤Ç¤Ï¡¢¤³¤Î¤Û¤«¡¢¥¢¥¸¥å¥Ð¥ó¥È¤¬Æþ¤Ã¤Æ¤¤¤Ê¤¤¡¢Ç¥ÉØÍѤΥ說¥Á¥ó¤È¤·¤Æ¡¢¥ª¡¼¥¹¥È¥é¥ê¥¢CSL Ltd¼Ò¤«¤é¡¢¡ÖPanvax¡×¤ò 200000Éþ¡¢Í¢Æþ¤·¤Æ¤¤¤Þ¤¹¡£

¤Ê¤ª¡¢»ä¤Î¥Ö¥í¥°µ­»ö¡ØH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥ï¥¯¥Á¥óÀܼï²ó¿ô¤Ï¡¢10ºÐ°Ê¾å¤Ï1²óÀܼï¤Ë¤¹¤Ù¤·¡Ù¤Ë°ÊÁ°10·î½é½Ü¤Ë½ñ¤­¤Þ¤·¤¿¤è¤¦¤Ë¡¢¥«¥Ê¥À¤Ç¤Ï¡¢65ºÐ°Ê¾å¤Î¤«¤¿¤Ë¡¢µ¨ÀáÀ­ÍѤΥ說¥Á¥ó¤òÀܼ魯¤ë¤È¡¢¤«¤¨¤Ã¤Æ¡¢H1N1¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤«¤«¤ê¤ä¤¹¤¯¤Ê¤ë¤Î¤Ç¡¢µ¨ÀáÀ­ÍÑ¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥ï¥¯¥Á¥ó¤ÎÀܼï¤Ï¡¢2010ǯ¤Ë¤Ê¤ë¤Þ¤Ç¡¢ÂԤ俤ۤ¦¤¬¤¤¤¤¡£¡×¤È¤Î¸¦µæÀ®²Ì¤¬the B.C. Centre for Disease Control¤«¤éȯɽ¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

¤³¤ì¤È¡¢º£²ó¤Î°ì·ï¤È¤Î´Ø·¸¤Ï¡¢º£¤Î¤È¤³¤í¤ï¤«¤Ã¤Æ¤¤¤Þ¤»¤ó¡£

¤Þ¤¢¡¢¤Á¤ç¤Ã¤È¡¢ÈéÆù¤Ê¸«Êý¤Ë¤Ï¤Ê¤ê¤Þ¤¹¤¬¡¢ÆüËܤǤϡ¢¤¹¤Ã¤¿¤â¤ó¤À¤ÎÀ¯Ì³´±¤ÎÀ¯¼£¼çƳ¤Î±¦±ýº¸±ý¤ÎËö¡¢¹ñ»º¥ï¥¯¥Á¥ó¤Î°ì²óÀܼ郎·è¤Þ¤ê¡¢·ë²Ì¡¢Åö½é·×²è¤Î¤«¤Ê¤ê¤Î¿ô¤ÎÍ¢Æþ¥ï¥¯¥Á¥ó¤¬ÉÔÍפȤʤꤽ¤¦¤Ê¤Î¤Ç¤¹¤«¤é¡¢¤³¤Î¥«¥Ê¥À¤Î°ì·ï¤ò¡¢¸üÀ¸Ï«Æ¯¾Ê¤Ï¡¢¥Í¥¿¤Ê¤ê°ø±ï¤Ê¤ê¥¹¥±¡¼¥×¥´¡¼¥È¤Ê¤êÅϤê¤ËÁ¥¤Ê¤ê¤Ë¤·¤Æ¡¢Í¢ÆþÂǤÁÀÚ¤ê¤Ç¤­¤ì¤Ð¡¢·ë²Ì¡¢Í¢Æþ¥ï¥¯¥Á¥ó²á¾êºß¸Ë¤Ø¤ÎÀÕǤƨ¤ì¤¬¤Ç¤­¤ë¤Î¤«¤â¤·¤ì¤Þ¤»¤ó¤Í¡£

°Ê¾å

»²¹Í
¥¢¥¸¥å¥Ð¥ó¥È(AS03)¤ÎÉûºîÍÑ(ÉûÈ¿±þ)¤È¤ß¤é¤ì¤Æ¤¤¤ë¾É¾õ¤Ë¤Ï¼¡¤Î¤â¤Î¤¬¤¢¤ë¤è¤¦¤Ç¤¹¡£

¡ÖALERT Canadians: Toxic Ingredients in the Arepanrix H1N1 Vaccine will Harm Your Health¡×¤«¤é

Pain(áÖÄË)
Redness(ȯÀÖ)
Swelling(¼ðı)
Fatigue(¤±¤óÂÕ´¶)
Headaches(ƬÄË)
Arthralgia (joint inflammation)(´ØÀáÄË)(´ØÀá¤Î±ê¾É)
Myalgia (muscle inflammation)(¶ÚÆùÄË)(¶ÚÆù¤Î±ê¾É)
Shivering(¿Ì¤¨)
Sweating(ȯ´À)
Swollen lymph nodes(¥ê¥ó¥ÑÀá¤Î¼ðÂç)
Fever(ȯǮ)
Vomiting(ÓÒÅÇ)
Tingling or numbness of the hands or feet(¼ê­¤Î¡¢¤¦¤º¡«¤­´¶¡¢¤Þ¤¿¤Ï¡¢¤·¤Ó¤ì´¶)
Shortness of breath(©ÀÚ¤ì)
Vasculitis (inflammation of the blood vessels)(·ì´É±ê)(·ì´É¤Î¼ðı)

Serious adverse reactions are as follows(°Ê²¼¤Ï¿¼¹ï¤ÊÍ­³²È¿±þ)

Blood and lymphatic system disorders (lymphadenopathy)(·ì±Õ¤ä¥ê¥ó¥Ñ·Ï°Û¾ï)(¥ê¥ó¥ÑÀá¼ðı¾É)

Psychiatric disorders (insomnia)(Àº¿À¾ã³²)(ÉÔ̲¾É)

Nervous system disorders (dizziness, paraesthesia, inflammation of the central nervous system, inflammation of nerves, autoimmune disorders affecting myelin sheaths of nerves such as Guillain-Barré Syndrome)(¿À·Ð·Ï¼À´µ)(Ìܤޤ¤.Ãγа۾ï¾ã³².Ãæ¿õ¿À·Ð·Ï±ê¾É.¿À·Ð±ê¾É.¥®¥é¥ó¥Ð¥ì¡¼¾É¸õ·²¤Î¤è¤¦¤Ê¿À·Ð¤Î¿ñ¾ä¤Ë±Æ¶Á¤òÍ¿¤¨¤¦¤ë¼«¸ÊÌȱְ۾ï.)

Ear and labyrinth disorders (vertigo)(¼ª¼À´µ¤ä¼ªÌÂÏ©¼À´µ)(Ìܤޤ¤)

Respiratory, thoracic and mediastinal disorders (dyspnoea)(¸ÆµÛ´ï¤ä¶»Éô¤ä½Ä³Ö¤Î°Û¾ï)(¸ÆµÛº¤Æñ)

Gastrointestinal disorders (nausea, diarrhea, abdominal pain, vomiting, dyspepsia, stomach discomfort)(°ßIJ°Û¾ï)(ÅǤ­µ¤.²¼Î¡.Ê¢ÄË.ÓÒÅÇ.¾Ã²½ÉÔÎÉ.°ß¤ÎÉÔ²÷´¶)

Skin and subcutaneous tissue disorders (pruritus, rash)(ÈéÉæ¤äÈé²¼ÁÈ¿¥¤Î°Û¾ï)(ÁßáÚ¾É.ȯ¿¾)

Musculoskeletal and connective tissue disorders (back pain, musculoskeletal stiffness, neck pain, muscle spasms, pain in extremity)(¶Ú¹ü³Ê°Û¾ï¡¢·ë¹çÁÈ¿¥°Û¾ï)(ÇØÄË.¶Ú¹ü³Ê¤Î¶Å¤ê.ðôÉôáÖÄË.¶ÚÚ»½Ì.»Í»è¤ÎÄˤß)

General disorders and administration site conditions (bruising, asthenia, chest pain, malaise)(¤µ¤Þ¤¶¤Þ¤Ê°Û¾ï´¶¡¢ÅêÍ¿Éô°Ì¤Î¾õÂÖ)(ºÃ½ý.̵ÎϾÉ.¶»ÄË.É԰´¶)

»²¹Í
¡ÖÍ¢Æþ¥ï¥¯¥Á¥ó¤Î°ÂÁ´À­¡¦Èó°ÂÁ´À­¡¡Ááʬ¤«¤ê°ìÍ÷¡×

Arepanrix¤Î»ÈÍÑÊýË¡¤Î¥Ó¥Ç¥ª

(¤³¤Î¥Ó¥Ç¥ª¤ò¸«¤ë¤è¤¦¤Ë¡¢Arepanrix¤Ï¡¢Æó¤Ä¤Î¥³¥ó¥Ý¡¼¥Í¥ó¥È(antigen¤Èadjuvant)¤«¤é¤Ê¤Ã¤Æ¤¤¤ë¤Î¤Ç¡¢Èó¾ï¤Ë´ÉÍý¤¬Æñ¤·¤¤¤È¤µ¤ì¤Æ¤¤¤ë¡£)


¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¥ï¥¯¥Á¥ó¤Î¥ê¥¹¥¯¤Ë¤Ä¤¤¤Æ¤ÎDr. Roby Mitchell¤Î¥Ó¥Ç¥ª


¥«¥Ê¥À¤Ç¤Î¥ï¥¯¥Á¥ó»ÈÍÑÃæ»ß¤òÅÁ¤¨¤ë¥Æ¥ì¥Ó


¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/22 Sunday

³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 19:01:49

¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø

¤³¤Î¾ðÊó¤Ï11·î22Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ­¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ­»ö¤Ç¤Ï¡¢²¼µ­¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ­»ö½ç¤Ç¤¹¡£

D225GÊÑ°ÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ(11·î25Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ(11·î19Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)

2009/11/22(Sun)
¡¡
­¡Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á 2,3 ·ë¹ç¤·¤¿¤â¤Î¡ÊSA¦Á2,3Gal¡Ë¤òǧ¼±¤·¡¢
¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¼ç¤È¤·¤Æ¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á2,6·ë¹ç¤·¤¿¤â¤Î (SA ¦Á2,6Gal )¤òǧ¼±¤¹¤ë¡£

­¢¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¡¢¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¤Ç¤Ï°Û¤Ê¤ë¡£

­£¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¡¢¥Ò¥È¤Î¾åÉôµ¤Æ»¤Î¾åÈéºÙ˦¤Ë¤·¤«¤Ê¤¤¡£

­¤Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¥Ò¥È¤Î¸ÆµÛ´ï¤Î¿¼Éô¡Ê¸ÆµÛºÙµ¤´É»Ù¤ÈÇÙ˦ºÙ˦¤Î°ìÉô¡Ë¤Ë¡¢Â¿¤¯Â¸ºß¤¹¤ë¡£

­¥¤³¤Î¥Ò¥È¤Î¸ÆµÛ´ï¤Ë¤ª¤±¤ë¥Ò¥È¡¦¥¦¥¤¥ë¥¹¤ÈÄ»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¥ì¥»¥×¥¿¡¼Ê¬ÉÛ¤ÎÁê°ã¤Ï¡¤H5N1 ¥¦¥¤¥ë¥¹¤¬¿Í¤«¤é¿Í¤ØÅÁÇŤ·¤Ë¤¯¤¤»ö¼Â¤Ë¤â´Ø·¸¤·¤Æ¤¤¤ë¡£

­¦¥Ò¥È¤¬Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ò¸úΨ¤è¤¯ÅÁÇŤ¹¤ë¤¿¤á¤Ë¤Ï¡¤HA ¤¬¥Ò¥È¡¦¥¦¥¤¥ë¥¹¤Î¥ì¥»¥×¥¿¡¼¤òǧ¼±¤Ç¤­¤ë¤è¤¦¤ËÊÑ°Û¤¹¤ëɬÍפ¬¤¢¤ë¡£

­§¥Ò¥È¤¬¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ë´¶À÷¤¹¤ë¤È¡¢½ÅÆƤʲ¼Éô¸ÆµÛ´ï¾ã³²¤ò°ú¤­µ¯¤³¤¹¤³¤È¤¬¤¢¤ë¤Î¤Ï¡¢¤³¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉÛ(¸ÆµÛ´ï¤Î¿¼Éô¤ËÄ»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¥ì¥»¥×¥¿¡¼¤¬¤¢¤ë¡£)¤Î°ã¤¤¤È¡¢¥¦¥¤¥ë¥¹¤ÎÊѰۤˤè¤ë¤È¤³¤í¤¬Â礭¤¤¤È¸«¤é¤ì¤ë¡£

­¨º£²ó¡¢¥¦¥¯¥é¥¤¥Ê¤Ç¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¡¢¤¤¤º¤ì¤â½ÅÆƤǡ¢¤·¤«¤â¡¢¤½¤Î»àË´¼Ô¤ò´Þ¤á¤¿½ÅÆƼԤÎÇ٤ǤΥ¦¥¤¥ë¥¹¤¬¡¢¤¤¤º¤ì¤â¡¢D225GÊÑ°Û¤ò¤ª¤³¤·¤ª¤ê¡¢¾åµ¤Æ»¤Ç¤ÎD225GÊÑ°Û¤¬1¤Ä¤·¤«¤Ê¤«¤Ã¤¿¤È¤¤¤¦¤³¤È¤¬¡¢¾åµ­¤Î¤³¤È¤È´Ø·¸¤¢¤ë¤Î¤«¡£

­©¥Ý¥¸¥·¥ç¥ó225ÊѰۤϡ¢H3N2¤Ë¤è¤¯¸«¤é¤ì¤ë¥¢¥Þ¥ó¥¿¥¸¥óÂÑÀ­ÊѰۤǤ¢¤ê¡¢H1N1¤Ë¤ª¤¤¤Æ¤â¡¢·à¾ÉÀ­¤òÉÕÍ¿¤·¤¦¤ëÊѰۤǤ¢¤ë¤µ¤ì¤Æ¤¤¤ë¡£

¥¢¥Þ¥ó¥¿¥¸¥óÂÑÀ­ÊѰۤǤ¢¤ë¤³¤È¤È¡¢¥¦¥¯¥é¥¤¥Ê¤È¤Î´Ø·¸¤Ï¤¢¤ë¤Î¤«?

­ª¤Þ¤¿¡¢1918ǯ¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤Ë¤ª¤¤¤Æ¡¢ºÎ¼è¤µ¤ì¤¿Æó¤Ä¤Î¥¦¥¤¥ë¥¹¡¡A/New York/1/1918 ¤È¡¡A/London/1/1919¡¡¤Ë¤â225¤Ë¤ª¤¤¤Æ¡¢Æ±ÍͤÎD225GÊÑ°Û¤¬¸«¤é¤ì¤¿¤³¤È¤È¤Î´Ø·¸¤Ï¤¢¤ë¤Î¤«¤É¤¦¤«¡£

­«1918ǯ¤Î¥¦¥¤¥ë¥¹¤Î¥·¡¼¥±¥ó¥¹Ê¬ÀϤˤª¤¤¤Æ¡¢¼õÍÆÂÎÆÃÀ­¤Ï¡¢¡ÖSA ¦Á2,6Gal¡× ¤È¡¢¡ÖSA¦Á2,3Gal¡×¤È¡¢¡ÖSA¦Á2,3Gal¤ÈSA ¦Á2,6Gal¤È¤Îº®¹ç¡×¤È¤Î»°¤Ä¤Î¥¿¥¤¥×¤¬¸«¤é¤ì¤¿¡£

­¬¼õÍÆÂÎÆÃÀ­¤Î¡ÖSA¦Á2,3Gal¡×¤«¤é¡ÖSA ¦Á2,6¡×¤Ø¤ÎÊѲ½¼«ÂΤϡ¢·à¾ÉÀ­¤òÉÕÍ¿¤¹¤ë¤â¤Î¤Ç¤Ï¤Ê¤¤¡£
¡ÖSA¦Á2,3Gal¤ÈSA ¦Á2,6Gal¤È¤Îº®¹ç¡×¤Ë¤Ä¤¤¤Æ¤Ï¤É¤¦¤«?

­­CDC¤ÎNancy J. Cox »á¤ò¤Ï¤¸¤á¤È¤¹¤ë59¿Í¤«¤é¤Ê¤ë¸¦µæ¥Á¡¼¥à¤ÎH1N1 ¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î°äÅÁ»ÒʬÀϤˤè¤ì¤Ð¡¢8¤Ä¤Î¥»¥°¥á¥ó¥È¤Î¤¦¤Á¡¢¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó(H)¤ò´Þ¤à3¤Ä¤Î°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ï¡¢1918ǯ¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤ÎH1N1¤ËͳÍ褹¤ë¤â¤Î¤Ç¤¢¤ê¡¢¤½¤Î¸å¡¢¤º¤Ã¤ÈÆڤ˸ºß¤·¤Æ¤¤¤¿¤â¤Î¤Ç¤¢¤ë¤¬¡¢¤½¤Î´Ö¤Ë¤ª¤¤¤Æ¤â¡¢ÊѰۤϤ·¤Æ¤¤¤Ê¤«¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ç¤Ï¡¢¥Ý¥ê¥á¥é¡¼¥¼B(PB)°äÅÁ»Ò¤Ï¥Ò¥ÈͳÍ衢¾¤ÎÆó¤Ä¤ÏĻͳÍè¤Ç¤¢¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
¤Þ¤¿¡¢1918ǯ¤ÎH1N1¤ÈH5N1¤È¤Ï¡¢ÆÇÀ­¤¬¤¢¤ë¤³¤È¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤ò¡¢Æ±¤¸NS1¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤ÆÍ­¤·¤Æ¤¤¤ë¤¬¡¢º£²ó¤Î¿·H1N1¤Ï¡¢¤½¤¦¤Ç¤Ï¤Ê¤¤¤È¤¤¤¦¡£
´¶À÷À­¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤Æ¤â¡¢º£²ó¤Î¿·H1N1¤Ï¡¢1918ǯ¤ÎH1N1¤Ë¤¢¤Ã¤¿¤â¤Î¤ò¼º¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¡£

»²¹Í¡¡´ØÏ¢¤¹¤ë»ä¤Î¥Ö¥í¥°µ­»ö

¡Ö¤ä¤Ï¤ê¿··¿¤Ç¤Ï¤Ê¤«¤Ã¤¿¡¢º£²ó¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¡×
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ¡×
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´¡×

¤½¤Î¾´ØÏ¢¥µ¥¤¥È
¡ÖRole of sialic acid binding specificity of the 1918 influenza virus hemagglutinin protein in virulence and pathogenesis in mice.¡×
¡Övirus: alpha2,6-sialyllactose-avian flu citations¡×

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/19 Thursday

¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 23:41:36

¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø

¤³¤Î¾ðÊó¤Ï11·î19Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ­¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ­»ö¤Ç¤Ï¡¢²¼µ­¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ­»ö½ç¤Ç¤¹¡£

D225GÊÑ°ÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ(11·î25Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ(11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)

2009ǯ11·î19Æü
¡¡
¤«¤Í¤Æ¤«¤é¤³¤Î¥Ö¥í¥°¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´¡×¤Ê¤É¤Ç¤âÅÁ¤¨¤Æ¤¤¤ë¥¦¥¯¥é¥¤¥Ê¤Ç¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤è¤ë»àË´¤À¤¬¡¢¤³¤³¤ËÍè¤Æ¡¢¤³¤ì¤Ë¤è¤ë»à¼Ô¤Ï¡¢344¿Í¤Ë㤷¤¿¤È¤Î¤³¤È¤Ç¤¢¤ë¡£

°ìÆü¤¢¤¿¤ê16¿Í¤º¤Ä»àË´¼Ô¤¬Áý²Ã¤·¤Æ¤¤¤ë¤È¤¤¤¦¥Ú¡¼¥¹¤Î¤è¤¦¤Ç¤¢¤ë¡£

¤³¤³¤ËÍè¤Æ¡¢¥¦¥¤¥ë¥¹¤Î¥·¡¼¥±¥ó¥¹¤âȯɽ¤µ¤ì¤¿¤¬¡¢¤³¤ì¤Ë¤è¤ë¤È¡¢10¸¡ÂΤΤ¦¤Á¡¢4¸¡ÂΤˡ¢HA¤Ë¤ª¤¤¤Æ¡¢D225GÊÑ°Û¤ò¼¨¤·¤Æ¤¤¤¿¤È¤¤¤¦¡£

D225GÊÑ°Û¤òµ¯¤³¤·¤Æ¤¤¤ë¥¦¥¤¥ë¥¹Ì¾¤Ï²¼µ­¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/Lviv/N6/2009
A/Ternopil/N11/2009
A/Ternopil/N10/2009
A/Lviv/N2/2009

¤³¤Î¤¦¤Á¡¢1¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢¹¢¤«¤é¤Î¤â¤Î¤Ç¤¢¤ê¡¢3¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢ÇÙÁÈ¿¥¤«¤é¤Î¤â¤Î¤Ç¤¢¤Ã¤¿¡£

¤³¤Î4¸¡ÂΤòºÎ¼è¤·¤¿´µ¼Ô¤Ï¤¤¤º¤ì¤â»àË´¼Ô¤Ç¤¢¤Ã¤¿¡£

É¡°öƬ¤«¤é¤Î¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢D225GÊѰۤϸ«¤é¤ì¤Ê¤«¤Ã¤¿¤È¤¤¤¦¡£

¤³¤Î¤³¤È¤«¤é¡¢D225GÊÑ°Û¤¬¡¢ÇÙÁÈ¿¥¤Ë½¸Ã椷¤Æ¸«¤é¤ì¤ë¤Î¤«¤É¤¦¤«¤¬¡¢´Ø¿´¤Î¤â¤È¤È¤Ê¤Ã¤Æ¤¤¤ë¤è¤¦¤À¡£

¤½¤Î¤¿¤á¤Ë¤Ï¡¢¤³¤ÎÇÙÁÈ¿¥¤«¤é¤Î¸¡ÂΤ¬É¡°öƬ¤«¤é¤ÎÇ´±Õ¤«¤é¤­¤Æ¤¤¤ë¤â¤Î¤«¤É¤¦¤«¤òÁáµÞ¤Ë¸¡ºº¤·¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¤È¤·¤Æ¤¤¤ë¡£

¤Ê¤¼¤Ê¤é¡¢¾åµ¤Æ»¤Ç¤Î¥¦¥¤¥ë¥¹¤¬¤Û¤È¤ó¤É¤Ê¤¯¡¢Ç٤˥¦¥¤¥ë¥¹¤¬½¸Ã椷¤Æ¤¤¤ë²ÄǽÀ­¤¬¶¯¤¤¤«¤é¤À¡£

¶Ëü¤Ë¤Ï¡¢É¡°öƬ¤«¤é¤Î¸¡ÂΤǤϡ¢±¢À­¤ò¼¨¤¹¤³¤È¤¹¤é¤¢¤ë¤«¤é¤À¡£

CDC¤Î¸«²ò¤Ç¤Ï¡¢¥é¥Ô¥Ã¥É¡¦¥Æ¥¹¥È¤Ç¤Ï¡¢10¥Ñ¡¼¥»¥ó¥È¤«¤é70¥Ñ¡¼¥»¥ó¥È¤Î¶Ò¤Ç¤Î´¶Å٤κ¹¤¬¤¢¤ë¤È¤¤¤¦¡£

¤·¤¿¤¬¤Ã¤Æ¡¢¾õ¶·¤Ë¤è¤Ã¤Æ¤Ï¡¢¼ÂÂÖ¤Î10¥Ñ¡¼¥»¥ó¥È¤·¤«¡¢ÍÛÀ­¤ò¼¨¤µ¤Ê¤¤¾ì¹ç¤â¤¢¤ë¤È¤¤¤¦¡£

±¢À­¤ò¼¨¤·¤Æ¤¤¤ë¥é¥Ô¥Ã¥É¡¦¥Æ¥¹¥È¤Î¥µ¥ó¥×¥ë¤Ï¡¢¤³¤Î¾ì¹ç¡¢¤è¤êÀººº¤ò¤¹¤ë¤³¤È¤¬É¬ÍפǤ¢¤ë¤È¤¤¤¦¡£

¤³¤ÎD225GÊÑ°Û¤¬ÇÙÁÈ¿¥¤Ë½¸Ã椷¤Æ¤¤¤ë¤È¤¤¤¦¤³¤È¤Ï¡¢H1N1¥¦¥¤¥ë¥¹¤¬ÇÙÁÈ¿¥¤Ë½¸Ã椷¤Æ¤¤¤ë¤³¤È¤ò°ÕÌ£¤·¤Æ¤ª¤ê¡¢¤³¤Î¤³¤È¤¬¡¢¥µ¥¤¥È¥«¥¤¥ó¸½¾Ý¤ò°ú¤­µ¯¤³¤·¤Æ¤¤¤ë¤È¸«¤ë¸þ¤­¤â¤¢¤ë¤è¤¦¤À¡£

¤³¤ÎD225GÊѰۤϡ¢¤³¤ì¤Þ¤Ç¡¢¤¹¤Ç¤Ë¡¢¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¡¢Ãæ¹ñ¡¦Zhejiang¡¢ÆüËÜ¡¦¹­Åç¡¢¥¢¥á¥ê¥«¡¦¥Æ¥­¥µ¥¹¡¢¥¢¥á¥ê¥«¡¦¥¸¥ç¡¼¥¸¥¢¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥è¡¼¥¯¡¢¥á¥­¥·¥³¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¤Ç¸«¤é¤ì¤¿ÊѰۤǤ⤢¤ë¡£

¤·¤«¤·¡¢D225GÊÑ°Û¤¬¸«¤é¤ì¤¿¤È¤¤¤¦¤³¤È¤Ï¡¢¤³¤Î¥¦¥¤¥ë¥¹¤Î°äÅÁ»ÒŪ¤ÊÎò»ËÇØ·Ê(multiple genetic backgrounds via recombination)¤ò¸ì¤ë¤â¤Î¤Ç¤¢¤ë¤È¤¹¤ë¸«Êý¤â¤¢¤ë¡£

¤¹¤Ê¤ï¤Á¡¢»°¼ï¤Î¥¦¥¤¥ë¥¹¤ÎºÆ·ë¹ç(triple reassortant viruses)¤Ë¤ß¤é¤ì¤ëÊѰۤǤ¢¤ë¤È¤¤¤¦Àâ¤Ç¤¢¤ë¡£

¤½¤ÎÍýͳ¤È¤·¤Æ¡¢1918ǯ¤«¤é1919ǯ¤Ë¤«¤±¤Æ¤Î¥¹¥Ú¥¤¥ó¤«¤¼¤Ë¤ª¤¤¤ÆºÎ¼è¤µ¤ì¤¿Æó¤Ä¤Î¥¦¥¤¥ë¥¹¡¡A/New York/1/1918 ¤È¡¡A/London/1/1919¡¡¤Ë¤â225¤Ë¤ª¤¤¤Æ¡¢Æ±ÍͤÎD225GÊÑ°Û¤¬¸«¤é¤ì¤¿¤³¤È¤Ë¤Ä¤¤¤Æ¤Î·üÇ°¤«¤éÍè¤Æ¤¤¤ë¤â¤Î¤Ç¤¢¤ë¡£

°ìÊý¡¢¥Î¥ë¥¦¥§¥¤¤Ë¤ª¤¤¤Æ¤â¡¢Æ±ÍͤÎÊÑ°Û¤ò»ý¤Ä´µ¼Ô¤¬È¯¸«¤µ¤ì¤¿¡£

H3¥Ê¥ó¥Ð¥ê¥ó¥°¤Ç¤Ï¡¢¥Ý¥¸¥·¥ç¥ó222¤¬¥Ý¥¸¥·¥ç¥ó225¤Ë¤¢¤¿¤ë¡£

¤Þ¤¿¡¢¥í¥·¥¢¤Ë¤ª¤¤¤Æ¤Ï¡¢A/Vladivostok/1/2009Æó¡¢Æ±ÍͤÎÊÑ°Û¤¬¸«¤Ä¤«¤Ã¤Æ¤¤¤ë¡£

¥Î¥ë¥¦¥§¥¤¤Î¾ì¹ç¤Ï¡¢70¿Í¤Ë¤Ä¤¤¤Æ¸¡ºº¤ò¤·¡¢¤½¤Î¤¦¤Á¡¢8¿Í¤Î´µ¼Ô¤Ï»àË´¤·¤Æ¤¤¤ë¡£

D225GÊÑ°Û¤¬¸«¤é¤ì¤¿¤Î¤Ï¡¢¤³¤Î¤¦¤Á¤Î5¿Í¤Ç¤¢¤ê¡¢¤½¤Î¤¦¤Á¤Î2¿Í¤Ï»àË´¤·¤Æ¤¤¤ë¡£

¾¤Î»°¿Í¤Ï¡¢½¸Ãæ¼£Îż¼¤ËÆþ¤Ã¤Æ¤ª¤ê¡¢½Å¾É¤Ç¤¢¤ë¡£

¤³¤³¤Ç¤â¡¢¥¦¥¯¥é¥¤¥Ê¤ÈƱ¤¸¤¯¡¢ÊÑ°Û¥¦¥¤¥ë¥¹¤Ï¡¢Ç٤˽¸Ã椷¤Æ¡¢È¯¸«¤µ¤ì¤Æ¤¤¤ë¤È¤¤¤¦¡£

¥Ý¡¼¥é¥ó¥É¤Ë¤ª¤¤¤Æ¤â¡¢¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤è¤ë»à¼Ô¤¬µÞÁý¤·¤Æ¤¤¤ë¤¬¡¢¤³¤ì¤é¤Ë¤âD225GÊÑ°Û¤¬¤¢¤Ã¤¿¤«¤É¤¦¤«¤Ë¤Ä¤¤¤Æ¤Ï¡¢º£¤Î¤È¤³¤í¡¢³Îǧ¤Ç¤­¤Æ¤¤¤Ê¤¤¤è¤¦¤À¡£

È÷¹Í

¤³¤ì¤Þ¤ÇD225GÊÑ°Û¤ò¤ß¤»¤¿¥¦¥¤¥ë¥¹Ì¾°ìÍ÷(¥¦¥¯¥é¥¤¥Êʬ¤ò½ü¤¯)

01¡¡A/******/index/2009/02/01 (A/swine-flu/index/2009-02-01(H1N1))
02¡¡A/Hiroshima/201/2009/06/17
03¡¡A/Georgia/01/2009/04/27
04¡¡A/Zhejiang-Yiwu/11/2009/09/06
05¡¡A/Zhejiang/DTID-ZJU03/2009/09/07
06¡¡A/Zhejiang/DTID-ZJU02/2009/09/07
07¡¡A/Sao Paulo/53206/2009/07/19
08¡¡A/Sao Paulo/53225/2009/08/01
09¡¡A/New York/04/2009/04/
10¡¡A/Catalonia/NS1706/2009/07/29
11¡¡A/Mexico/InDRE4114/2009//
12¡¡A/Texas/11/2009/04/23
13¡¡A/Texas/05/2009/04/15
14¡¡A/Mexico/3955/2009/04/02
15¡¡A/Cancun-NY/Index/2009/04/15

»²¹Í
¡ÖH5N1Experts.org - View Single Post - swine flu sequences ¡×
my supposed index-strain , the virus which I consider the best candidate¡¡for the original ancestor virus of all ****** .
Presumably the virus¡¡which jumped from swine to a human or (IMO less likely) which reassorted in a human

A/swine-flu/index/2009-02-01(H1N1)
A/******-match/1-2/07(H3N2)¡¡(A/Mexflu-match/1-2/07(H3N2))
A/Sw/Index/triple-reassortant/1998(H3N2)

»²¹Í
¡ÖAntigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans¡×

»²¹Í
¡ÖA/Mexflu-match/1-2/07(H3N2)¡×

»²¹Í
¡ÖUkraine Dead Increase to 344 - Sequences Released¡×

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/09 Monday

¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 06:51:34

¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø

¤³¤Î¾ðÊó¤Ï11·î9Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ­¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ­»ö¤Ç¤Ï¡¢²¼µ­¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ­»ö½ç¤Ç¤¹¡£
D225GÊÑ°ÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ(11·î25Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ(11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ(11·î19Æü»þÅÀ)

2009ǯ11·î9Æü
¡¡
¥¦¥¯¥é¥¤¥Ê¤Ç¡¢¤³¤Î2½µ´Ö¤Ç¡¢80̾¤¬¸ÆµÛ´ï¼À´µ¤Ç»àË´¤·¤Æ¤ª¤ê¡¢¸½ºß¡¢Æ±ÍͤμÀ´µ¤Î´µ¼Ô¤¬40Ëü¿Í¤¤¤ë¤È¤¤¤¦¡£

¤½¤Î¤¤¤º¤ì¤â¡¢H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤«¤«¤Ã¤Æ¤¤¤ë¤È¤³¤í¤«¤é¡¢¡¢WHO¤«¤é¡¢Èó¾ï»öÂÖ¥Á¡¼¥à¤¬Çɸ¯¤µ¤ì¡¢¸½ÃϤǴƻë¤ËÅö¤¿¤Ã¤Æ¤¤¤ë¡£

¥¦¥¯¥é¥¤¥ÊÀ¯Éܤϡ¢³Ø¹»¤äÂç³Ø¤Î»°½µ´Ö¤ÎÊĺ¿¤ò·è¤á¡¢³Æ¼ï¥¤¥Ù¥ó¥È¤Î¼è¤ê¤ä¤á¤â·è¤á¤¿¡£

¥¦¥¯¥é¥¤¥ÊÂçÅýÎΤϡ¢¸½ºß¡¢»°¼ïÎà¤Î¥¦¥¤¥ë¥¹¤¬´¶À÷¤È¤Æ¤¤¤ë¤È¤·¡¢¤½¤ÎÊѰۤˤĤ¤¤Æ´í×ü¤·¤Æ¤¤¤ë¤È¤¤¤¦¡£

WHO¤Î¶ÛµÞ»öÂÖ¥Á¡¼¥à¤Ï¡¢´µ¼Ô¤«¤é9¤Ä¤Î¥µ¥ó¥×¥ë¤ò¡¢¥í¥ó¥É¥ó¤Î¥ß¥ë¥Õ¥£¥ë¤Ë¤¢¤ë¸¦µæ¥»¥ó¥¿¡¼¤Ë»ý¤Áµ¢¤ê¡¢¤½¤ÎʬÀϤËÅö¤¿¤Ã¤Æ¤¤¤ë¡£

ʬÀÏ·ë²Ì¤Î¾ÜºÙ¤Ï¡¢ÌÀ¤é¤«¤Ë¤µ¤ì¤Æ¤Ï¤¤¤Ê¤¤¤¬¡¢Â礭¤ÊÊѰۤϡ¢¸«¤é¤ì¤º¡¢¾®¤µ¤ÊÊѰۤˤȤɤޤäƤ¤¤ë¤È¤¤¤¦¡£

¥Ë¡¼¥Þ¥óÇî»Î¤Ï¡¢¥Ý¥¸¥·¥ç¥ó225¤Ç¤ÎÊѰۤǤϤʤ¤¤«¤È¤·¤Æ¤¤¤ë¡£

¥Ý¥¸¥·¥ç¥ó225ÊѰۤϡ¢H3N2¤Ë¤è¤¯¸«¤é¤ì¤ë¥¢¥Þ¥ó¥¿¥¸¥óÂÑÀ­ÊѰۤǤ¢¤ê¡¢H1N1¤Ë¤ª¤¤¤Æ¤â¡¢·à¾ÉÀ­¤òÉÕÍ¿¤·¤¦¤ëÊѰۤǤ¢¤ë¤µ¤ì¤Æ¤¤¤ë¡£¡£

¥Ý¥¸¥·¥ç¥ó225¤Ç¤ÎÊѰۤȤ·¤Æ¤Ï¡¢
D225N(¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¤ä¥Ë¥å¡¼¥è¡¼¥¯¤Ç¸«¤é¤ì¤¿ÊÑ°Û).
D225G(¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¡¢Ãæ¹ñ¡¦Zhejiang¡¢ÆüËÜ¡¦¹­Åç¡¢¥¢¥á¥ê¥«¡¦¥Æ¥­¥µ¥¹¡¢¥¢¥á¥ê¥«¡¦¥¸¥ç¡¼¥¸¥¢¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥è¡¼¥¯¡¢¥á¥­¥·¥³¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¤Ç¸«¤é¤ì¤¿ÊÑ°Û).
D225E(ÆüËÜ¡¦Ä¹ºê¡¢ÆüËÜ¡¦»¥ËÚ¡¢Ãæ¹ñ¡¦¹á¹Á¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥¸¥ã¡¼¥¸¡¼¡¢¥¢¥á¥ê¥«¡¦¥«¥ê¥Õ¥©¥ë¥Ë¥¢¡¢¥Õ¥é¥ó¥¹¡¦¥Ñ¥ê¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¡¢ ¥«¥¶¥Õ¥¹¥¿¥ó¡¦¥¢¥ë¥Þ¥È¥¤¡¢Ãæ¹ñ¡¦Ä¹º»¡¢¥¤¥¿¥ê¥¢¡¦¥ß¥é¥Î¡¢¥¤¥¿¥ê¥¢¡¦¥¢¥ó¥³¡¼¥Ê¡¢¥®¥ê¥·¥ã¡¦¥¢¥Æ¥Í¡¢¤Ç¸«¤é¤ì¤¿ÊÑ°Û)
¤ÎÊÑ°Û¤¬¤¹¤Ç¤Ë¡¢³Æ¹ñ¤Ç¸«¤é¤ì¤Æ¤¤¤ë¤È¤¤¤¦¡£

¥¦¥¯¥é¥¤¥Ê¤ËÎÙÀܤ¹¤ë¥ª¡¼¥¹¥È¥ê¥¢¡¢¥Ï¥ó¥¬¥ê¡¼¡¢¥¹¥í¥Ù¥Ë¥¢¤Ï¡¢¥¦¥¯¥é¥¤¥Ê¤ËÂФ·¤Æ¡¢¥ï¥¯¥Á¥ó¤ä¾ÃÆDZդαç½õ¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£

¥¦¥¯¥é¥¤¥Ê¤È¹ñ¶­¤òÀܤ·¤Æ¤¤¤ë¥¹¥í¥Ù¥Ë¥¢¤Ç¤Ï¡¢Àܤ·¤Æ¤¤¤ë5¤Ä¤Î¹ñ¶­¥é¥¤¥ó¤Î¤¦¤Á¡¢2¤Ä¤òÉõº¿¤·¤¿¡£

¥¦¥¯¥é¥¤¥Ê¤Ç¤Ï¡¢¤¹¤Ç¤Ë°åÌôÉʤä¥Þ¥¹¥¯¤Ê¤É¤ÎÉÔ­¾õÂ֤˴٤äƤ¤¤ë¡£

°ìÊý¡¢¤³¤Î»öÂ֤ϡ¢ÂçÅýÎΤȼóÁ꤬Á褦1·î¤ÎÂçÅýÎÎÁªµó¤Ë¤â¡¢Â礭¤¯±Æ¶Á¤¹¤ë¤â¤Î¤È¸«¤é¤ì¤Æ¤¤¤ë¡£

»²¹Í
¡ÖSwine Flu Outbreak Sparks Mutation Fears ¡×
¡ÖH1N1 Genetic Changes in RBD Raise Pandemic Concerns¡×

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

Ç­¤¬H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë´¶À÷¤È¤Î¥Ë¥å¡¼¥¹

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 06:32:33

2009ǯ11·î9Æü
¡¡
¥¢¥á¥ê¥«¡¦¥¢¥¤¥ª¥ï½£¤Î13ºÐ¤Î»ô¤¤Ç­¤¬¡¢¿··¿H1N1¤Ë¤«¤«¤Ã¤¿¤È¡¢Åö¶É¤¬È¯É½¤·¤¿¡£

¤³¤ÎÇ­¤Î»ô¤¤¼ç¤â¡¢¿··¿H1N1¤Ë´¶À÷¤·¤Æ¤¤¤ë¤È¤¤¤¦¡£

¤¹¤Ç¤Ë¡¢Ç­¤â»ô¤¤¼ç¤â¡¢²óÉü¤·¤Æ¤¤¤ë¤È¤¤¤¦¡£

¤ª¤½¤é¤¯¡¢º£²ó¤Î¿··¿H1N1¤Ç¡¢Ç­¤¬´¶À÷¤·¤¿¤Î¤Ï½é¤á¤Æ¤Î¤è¤¦¤Ç¡¢¥Ú¥Ã¥È°¦¹¥¼Ô¤Ë¶²Éݤò¸Æ¤Óµ¯¤³¤·¤Æ¤¤¤ë¤è¤¦¤À¡£

¤³¤Î¤³¤È¤ËÂФ·¤Æ¡¢ÀìÌç²È¤Ï¡¢¼¡¤Î¤è¤¦¤Ë¤¤¤Ã¤Æ¤¤¤ë¡£

¡Ö¤³¤Î¤³¤È¤Ï¡¢²¿¤âÄÁ¤·¤¤¤³¤È¤Ç¤Ï¤Ê¤¯¡¢¥Õ¥§¥ì¥Ã¥È¤ä²ÈÃܤˤ⤫¤«¤Ã¤Æ¤¤¤ë¤³¤È¤À¡£

º£¤Î¤È¤³¤í¡¢Ç­¢ªÇ­¢ª¿Í´Ö¤Ø¤Î´¶À÷¤È¤¤¤¦¤³¤È¤Ï¸«¤é¤ì¤Ê¤¤¡£

¤·¤«¤·¡¢¼ï¤«¤é¼ï¤Ø¤Î´¶À÷¤Ï¤¢¤ê¤¦¤ë¤³¤È¤À¡£

¤Þ¤¿¡¢¤³¤Î´¶À÷¤Î²áÄø¤Ç¡¢¥¦¥¤¥ë¥¹¤¬ÊÑ°Û¤¹¤ë¤«¤É¤¦¤«¤À¤¬¡¢¤¤¤Þ¤Î¤È¤³¤í¡¢³Îǧ¤µ¤ì¤Æ¤¤¤Ê¤¤¡£

Ç­¤¬¡¢Ç®¤¬¤¢¤Ã¤¿¤ê¡¢ÆÍÁ³Ì²¤¯¤Ê¤Ã¤¿¤ê¡¢¸µµ¤¤¬¤Ê¤¯¤Ê¤Ã¤¿¤è¤¦¤Ç¤¢¤Ã¤¿¤é¡¢¤¹¤°¡¢¸¡ºº¤ò¤·¤¿¤Û¤¦¤¬¤¤¤¤¡£

¤Þ¤¿¡¢Ç­¤¬Ê̤Ëɵ¤¤ò»ý¤Ã¤Æ¤¤¤ë¾ì¹ç¤Ë¤Ï¡¢¿Í´Ö¤ÈƱ¤¸¤è¤¦¤Ë¡¢¹çÊ»¾É¤¬¤ª¤³¤ë¡£

º£¤Î¤È¤³¤í¡¢Ç­¤ËÂФ¹¤ë¥ï¥¯¥Á¥ó¤Ï¤Ê¤¤¡£¡×

°Ê²¼¤Ï¡¢¤½¤ÎÇ­¤Î¥Ó¥Ç¥ª¤Ç¤¹¡£


»²¹Í
¡ÖVeterinarians try to calm H1N1 fears¡×
¡ÖH1N1 virus has started to threaten cats too!!!¡×

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/02 Monday

Í¢Æþ¥ï¥¯¥Á¥ó¤Î°ÂÁ´À­¡¦Èó°ÂÁ´À­¡¡Ááʬ¤«¤ê°ìÍ÷

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 04:51:18

¶ÛµÞÄɲÃ(2009ǯ11·î23Æü)

ËÜÆüÊóÆ»¤µ¤ì¤Æ¤ª¤ê¤Þ¤¹¡¢¥«¥Ê¥À¤Ç»ÈÍѶػߤˤʤä¿¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥ï¥¯¥Á¥ó¤Î¾ÜºÙ¤Ë¤Ä¤­¤Þ¤·¤Æ¤Ï¡¢Ê̤Υµ¥¤¥È¤òÀߤ±¤Þ¤·¤¿¡£

¡Ö¥«¥Ê¥À¤Ç»ÈÍÑÃæ»ß¤È¤Ê¤Ã¤¿¥ï¥¯¥Á¥ó¤Ë¤Ä¤¤¤Æ¤Î¾ÜºÙ¾ðÊó¡×
¤Ë¤ª±Û¤·¤¯¤À¤µ¤¤¡£

2009ǯ10·î23Æü
¡¡

Í¢Æþ¥ï¥¯¥Á¥ó¤Î°ÂÁ´À­¡¦Èó°ÂÁ´À­¤òÍý²ò¤¹¤ë¤¿¤á¤Î10¤Î¥Ý¥¤¥ó¥È

­¡º£²ó¤ÎÆüËܤؤÎÍ¢Æþ¥ï¥¯¥Á¥ó¤Ï¡¢Æó¼Ò¤È¤â¡¢¥¹¥¯¥ï¥ì¥ó¤ò»ÈÍѤ·¤¿¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¥ï¥¯¥Á¥ó¤Ç¤¢¤ë¡£

­¢¥¹¥¯¥ï¥ì¥ó¤ò»ÈÍѤ·¤¿¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤ë¥ï¥¯¥Á¥ó¤Ë¤Ï¥ê¥¹¥¯¤¬¤¢¤ë¡£

­£º£²ó¤ÎÆüËܤØÍ¢Æþ¤µ¤ì¤ë¥ï¥¯¥Á¥ó¤ÏÆó¼Ò¡¢°Û¤Ê¤Ã¤¿¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤ë¡£
¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¤Î¥¢¥¸¥å¥Ð¥ó¥È¤ÏAS03¡¢¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¤Î¥¢¥¸¥å¥Ð¥ó¥È¤ÏMF59¤Ç¤¢¤ë¡£
¥¢¥¸¥å¥Ð¥ó¥ÈAS03¤È¥¢¥¸¥å¥Ð ¥ó¥ÈMF59 ¤È¤Ç¤Ï¥ê¥¹¥¯¤¬°Û¤Ê¤ë

­¤¥¢¥¸¥å¥Ð¥ó¥È¤Ë´Þ¤Þ¤ì¤ë³¦Ì̳èÀ­ºÞ¤Ç¤¢¤ëTween 80(¥¢¥¸¥å¥Ð¥ó¥ÈAS03¤È¥¢¥¸¥å¥Ð ¥ó¥ÈMF59¤ÎξÊý¤Ë´Þ¤Þ¤ì¤Æ¤¤¤ë¡£)¤ÈSpan85(¥¢¥¸¥å¥Ð ¥ó¥ÈMF59¤Ë¤Î¤ß´Þ¤Þ¤ì¤Æ¤¤¤ë¡£)¤¬ÉÔÇ¥¤Ê¤É¤Î¸¶°ø¤È¤ÎÀ⤬¤¢¤ë¡£

­¥¥¹¥¯¥ï¥ì¥ó¤ò»ÈÍѤ·¤¿¥¢¥¸¥å¥Ð¥ó¥È¤Ë¤Ï¡¢¥¤¥ó¥¿¡¼¥í¥¤¥­¥ó£¶¤ÎÁý²Ã¤Ë¤è¤ë¥µ¥¤¥È¥«¥¤¥ó¤Î¥ê¥¹¥¯¤ÈÏÑ´ßÀïÁè¾É¸õ·²¤Î¥ê¥¹¥¯¤¬¤¢¤ë¤È¤¤¤ï¤ì¤Æ¤¤¤ë¡£

­¦º£²ó¡¢ÆüËܤËÍ¢Æþ¤µ¤ì¤ëÆó¼Ò¤Î¥ï¥¯¥Á¥óÀ½Â¤²áÄø¤Ë¤ª¤±¤ë¥¦¥¤¥ë¥¹ÇÝÍÜÊýË¡¤Ï¡¢Æ±¤¸¤Ç¤Ï¤Ê¤¯¡¢Æó¼Ò¡¢°Û¤Ê¤Ã¤Æ¤¤¤ë¡£
¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¤Ï¡¢È¯°é·ÜÍñÇÝÍÜË¡(embryonated egg culture)¤Ë¤è¤Ã¤Æ¤ª¤ê¡¢
¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¤Ï¡¢ÁÈ¿¥ÇÝÍÜË¡(cell culture)¤Ë¤è¤Ã¤Æ¤¤¤ë¡£

­§¸å¼Ô¤ÎưʪͳÍè¤ÎMDCKÁÈ¿¥¤ò»È¤Ã¤Æ¤ÎÁÈ¿¥ÇÝÍܥ說¥Á¥ó(cell culture vaccine ¡¢¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¤Î¥ï¥¯¥Á¥ó¤Î¤ß¡£)¤Ï¡¢¤½¤ÎͶƳÂΤǤ¢¤ëMDCK-T1¤Ë¼ðá縶À­¥ê¥¹¥¯¤¬¤¢¤ë¤È¤ÎÀ⤬¤¢¤ë¡£

­¨º£²óÆüËܤ¬Í¢Æþ¤Î¥°¥é¥¯¥½¤Î¥ï¥¯¥Á¥ó¡Ö¥Ñ¥ó¥Ç¥à¥ê¥¯¥¹¡×(Pandemrix)¤Ï¡¢¥â¥Ã¥¯¥¢¥Ã¥×(mock-up)¥ï¥¯¥Á¥ó¡ÊÂоݤȤ¹¤ë¥¦¥¤¥ë¥¹³ô¤¬ÆÃÄꤵ¤ì¤Æ¤¤¤Ê¤¤Ãʳ¬¤Ç¡¢¥â¥Ç¥ë¥¦¥¤¥ë¥¹¤òÍѤ¤¤ÆºîÀ½¤µ¤ì¤¿¥ï¥¯¥Á¥ó¡¢À½Â¤¾µÇ§¤Ï¤³¤ÎÃʳ¬¤ÇÆÀ¤Æ¤¤¤ë¡Ë¤Ç¤¢¤ê¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹H5N1Âбþ¥ï¥¯¥Á¥ó¤È¤·¤Æ³«È¯¤µ¤ì¤¿¥ï¥¯¥Á¥ó¤Î¥â¥Ç¥ë¥¦¥¤¥ë¥¹¤ò¡¢A/Vietnam/1194/2004(H5N1)¤«¤éA/California/7/2009 (H1N1)¤ËÆþ¤ìÂؤ¨¤Æ¡¢À½Â¤¤·¤Æ¤¤¤ë¤â¤Î¤Ç¤¢¤ë¡£

¥Î¥Ð¥ë¥Æ¥£¥¹¤Î¥ï¥¯¥Á¥ó¡Ö¥Õ¥©¥»¥È¥ê¥¢¡×(Focetria)¤Ï¥â¥Ã¥¯¥¢¥Ã¥×(mock-up)¥ï¥¯¥Á¥ó¤Ç¤¢¤ë¤¬¡¢¡Ö¥»¥ë¥È¥å¥é¡×(Celtura)¤Ï¡¢¥â¥Ã¥¯¥¢¥Ã¥×(mock-up)¥ï¥¯¥Á¥ó¤Ç¤Ï¤Ê¤¤¡£

­©¥¢¥á¥ê¥«¤Ï¡¢º£²ó¡¢¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤ÎÁªÄê¤ËÅö¤¿¤Ã¤Æ¡¢
¥¢¥¸¥å¥Ð¥ó¥È¤Ê¤·¤Î¥ï¥¯¥Á¥ó
¤Ç¤¢¤ê¡¢
MDCKÁÈ¿¥¤ò»È¤Ã¤Æ¤ÎÁÈ¿¥ÇÝÍܤÎÀ½Ë¡¤Ë¤è¤é¤Ê¤¤¥ï¥¯¥Á¥ó
¤òÁª¤ó¤À¡£

­ª¤³¤ì¤ËÂФ·¡¢ÆüËܤǤϡ¢Í¢Æþ¡¦¹ñ»ºÎ¾¥ï¥¯¥Á¥ó¸ò¤¨¤Æ¡¢
¥¢¥¸¥å¥Ð¥ó¥È¤¢¤ê¤Î¥ï¥¯¥Á¥ó(Í¢Æþ)¤È¥¢¥¸¥å¥Ð¥ó¥È¤Ê¤·¤Î¥ï¥¯¥Á¥ó(¹ñ»º)
¤È¤¬¤¢¤ê¡¢
¤·¤«¤â¡¢
¥¢¥¸¥å¥Ð¥ó¥È¤¢¤ê¤Î¥ï¥¯¥Á¥ó(Í¢Æþ)¤Ç¤Ï¡¢
°Û¤Ê¤Ã¤¿¥¢¥¸¥å¥Ð¥ó¥È(AS03¤ÈMF59)¤ò»È¤Ã¤¿¥ï¥¯¥Á¥ó
¤ä
°Û¤Ê¤Ã¤¿¥¦¥¤¥ë¥¹ÇÝÍÜË¡(ȯ°é·ÜÍñÇÝÍÜË¡¤ÈÁÈ¿¥ÇÝÍÜË¡)
¤Ç¤Î¥¢¥¸¥å¥Ð¥ó¥È¤¢¤ê¤Î¥ï¥¯¥Á¥ó¤¬¤¢¤ê¡¢

Í¢Æþ¥ï¥¯¥Á¥ó¤Î¤¦¤Á¤Î°ì¤Ä(¥°¥é¥¯¥½¤Î¥ï¥¯¥Á¥ó)¤Ï¡¢¥â¥Ç¥ë¡¦¥¦¥¤¥ë¥¹¤ò¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹(H5N1)¤«¤é¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹(H1N1)¤Ø¥·¥Õ¥È¤µ¤»¤¿¥â¥Ã¥¯¥¢¥Ã¥×¡¦¥ï¥¯¥Á¥ó¤Ç¤¢¤ê

¤³¤ì¤é¤¬º®ºß¤·¤Æ¡¢
¥â¥Ã¥¯¥¢¥Ã¥×¡¦¥ï¥¯¥Á¥óÃʳ¬¤Ç¤Î¼£¸³¤â´Þ¤á¤Æ¤Î¡¢¤ï¤º¤«¤Ê¼£¸³¤Î¸µ¤ËÀܼ蘆¤ì¤è¤¦¤È¤·¤Æ¤¤¤ë¡£

»²¹Í

¥¹¥¤¥¹À¯ÉܤÏ10·î£³£°Æü¡¢¥Î¥Ð¥ë¥Æ¥£¥¹¤È¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶Íѥ說¥Á¥ó¤òǧ²Ä¤·¤¿¤Èȯɽ¤·¤¿¡£
¤¿¤À¡¢

¥°¥é¥¯¥½¤Î¥ï¥¯¥Á¥ó¡Ö¥Ñ¥ó¥Ç¥à¥ê¥¯¥¹¡×(Pandemrix)¤Ë¤Ä¤¤¤Æ¤Ï¡¢

À®¿Í¤Ë¤Ä¤¤¤Æ¤Î¥Ç¡¼¥¿¤Ï½½Ê¬¤Ç¤¢¤ë¡£
¤·¤«¤·¡¢Ç¥ÉؤˤĤ¤¤Æ¤ÎɬÍ×Î×¾²¥Ç¡¼¥¿¤Ï¡¢¤Þ¤Ã¤¿¤¯¤Ê¤¤¡£
£±£¸ºÐ̤Ëþ¤Î»Ò¶¡¤Ë¤Ä¤¤¤Æ¤ÎɬÍ×Î×¾²¥Ç¡¼¥¿¤ÏÉÔ½½Ê¬¤Ç¤¢¤ë¡£
¤³¤ÎÍýͳ¤«¤é¡¢SwissMedic¤È¤·¤Æ¤Ï¡¢¡Ö¥Ñ¥ó¥Ç¥à¥ê¥¯¥¹¡×(Pandemrix)¤ÎÇ¥Éؤȣ±£¸ºÐ̤Ëþ¤Î»Ò¶¡¤È£¶£°ºÐ°Ê¾å¤ÎÀ®¿Í¤Ø¤Îǧ²Ä¤òαÊݤ¹¤ë¡£
¤·¤«¤·¡¢£¶£°ºÐ°Ê¾å¤ÎÀ®¿ÍÃ˽÷¤Ø¤ÎÀܼï¤Ë¤Ä¤¤¤Æ¤Ï¡¢¥¹¥¤¥¹±ÒÀ¸¶É(FOPH.Federal Office of Public Health )¤Î´«¹ð¤Î¤â¤È¤Ç¤¢¤ì¤Ð»È¤¦¤³¤È¤¬¤Ç¤­¤ë¡£

¥Î¥Ð¥ë¥Æ¥£¥¹¤Î¥ï¥¯¥Á¥ó¡Ö¥Õ¥©¥»¥È¥ê¥¢¡×(Focetria)¤Ë¤Ä¤¤¤Æ¤Ï¡¢

¤¹¤Ç¤Ë¡¢²¤½£°åÌôÉÊ¿³ººÄ£(EMEA.European Medicines Agency)¤Îǧ²Ä¤¬½Ð¤Æ¤¤¤ë¤Î¤Ç¡¢SwissMedic¤È¤·¤Æ¤Ï¡¢EMEA¤Îǧ²Ä·èÄê¤ò´ð¤Ë¤¹¤ë¡£
¤³¤ì(EMEA¤Îǧ²Ä)¤Ë½¾¤¨¤Ð¡¢¡Ö¥Õ¥©¥»¥È¥ê¥¢¡×(Focetria)¤Ï¡¢À®¿ÍÃ˽÷¤ÈÀ¸¸å£¶¥«·î°Ê¾å¤Î»Ò¶¡¤Ø¤Î»ÈÍѤò´«¹ð¤¹¤ë¡£
Ç¥»ºÉؤȡ¢¼øÆýÊì¤Ø¤ÎÀܼï¤Ë¤Ä¤¤¤Æ¤Ï¡¢¥¹¥¤¥¹±ÒÀ¸¶É(FOPH.Federal Office of Public Health )¤ÎºÇ¿·¤Î´«¹ð¤Ë±è¤Ã¤Æ¡¢¼ç¼£°å¤¬¡¢ÀøºßŪ¤ÊÍøÅÀ¤È·çÅÀ¤Ë¤Ä¤¤¤Æ¡¢Èæ³Ó¸¡Æ¤¤·¡¢Àܼï¤Î̵ͭ¤ò·èÄꤷ¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¡£

¥Î¥Ð¥ë¥Æ¥£¥¹¤Î¥ï¥¯¥Á¥ó¡Ö¥»¥ë¥È¥å¥é¡×(Celtura)¤Ë¤Ä¤¤¤Æ¤Ï¡¢

SwissMedic¤È¤·¤Æ¤Ï¡¢¸½ºß¡¢¤³¤Î¥ï¥¯¥Á¥ó¤ÎNobel Combination¤Ë¤Ä¤¤¤Æ¡¢»î¸³Ãæ¤Ç¤¢¤ë¡£
¤Ê¤ª¡¢º£²ó¡¢SwissMedic¤¬¡¢¤³¤Î¡Ö¥»¥ë¥È¥å¥é¡×(Celtura)¤Ë¤Ä¤¤¤Æ¡¢¤Ï¤Ã¤­¤ê¤·¤¿¥³¥á¥ó¥È¤ò¤·¤Æ¤¤¤Ê¤¤¤Ò¤È¤Ä¤ÎÍýͳ¤È¤·¤Æ¡¢¡Ö¥»¥ë¥È¥å¥é¡×(Celtura)¤Î¥Ð¥¯¥Æ¥ê¥¢±øÀ÷¤Î²ÄǽÀ­¤¬»ØŦ¤µ¤ì¤Æ¤¤¤ë¡£
the Swiss daily Tages-Anzeiger ¤Î¥ì¥Ý¡¼¥È¤Ë¤è¤ë¤È¡¢SwissMedic¤Ï¡¢¡Ö¥»¥ë¥È¥å¥é¡×(Celtura)¤Îtest batches¤Ë¡¢¥Ð¥¯¥Æ¥ê¥¢±øÀ÷¤ò¤ß¤Ä¤±¤¿¤È¤¤¤¦¡£
SwissMedic¤Ï¡¢¤³¤Î¥ì¥Ý¡¼¥È¤òÈÝÄê¤â¹ÎÄê¤â¤·¤Æ¤¤¤Ê¤¤¤È¤¤¤¦¡£
°ìÊý¡¢¥Î¥Ð¥ë¥Æ¥£¥¹Â¦¤Ï¡¢¡Ö¥Ð¥¯¥Æ¥ê¥¢¤Î±øÀ÷¤Ï¤Ê¤¯¡¢¤³¤ÎÁÈ¿¥ÇÝÍÜË¡¤Î²áÄø¤Ï¡¢È¯°é·ÜÍñÇÝÍÜË¡¤è¤ê¤â¡¢¥¯¥ê¡¼¥ó¤Ç¤¢¤ê¡¢¤³¤ÎÀ½Â¤²áÄø¤Ï¡¢¤³¤³¿ôǯ¤ÎƱ¼Ò¥ï¥¯¥Á¥ó¤ÎÀ½Â¤²áÄø¤ÈƱ¤¸¤â¤Î¤Ç¤¢¤ë¡£¡×¤È¡¢¤·¤Æ¤¤¤ë¡£
¤·¤«¤·¡¢¤³¤Î¡Ö¥»¥ë¥È¥å¥é¡×(Celtura)¤Ï¡¢ÆüËܤ¬Í¢Æþ¤¹¤ë¥ï¥¯¥Á¥ó¤Î¤Ò¤È¤Ä¤È¤µ¤ì¤Æ¤ª¤ê¡¢º£¸å¤ÎSwissMedicµÚ¤Ó¡¢EU¤Ç¤Î°ÂÁ´À­¤Î³Îǧ¤ËÃíÌܤ¹¤ëɬÍפ¬¤¢¤ë¡£

»²¾È¥µ¥¤¥È¡ÖSwissmedic grants authorisations for pandemic flu vaccines¡×
¡ÖSwitzerland restricts use of GlaxoSmithKline swine flu vaccine¡×
¡ÖNovartis denies problems with swine flu vaccine ¡×
¡ÖDie wichtigsten Infos zur Schweinegrippe-Impfung¡×)

°Ê²¼¤Ï¡¢¤½¤Î¤½¤ì¤¾¤ì¤Ë¤Ä¤¤¤Æ¤Î¾ÜºÙÀâÌÀ¤Ç¤¢¤ë¡£

­¡Í¢Æþ¥ï¥¯¥Á¥ó¤Ï¡¢Æó¼Ò¤«¤é

Ìó£·£·£°£°Ëü¿Íʬ¤Î¤¦¤Á¡¢4950Ëü¿Íʬ¤ÏÍ¢Æþ¥ï¥¯¥Á¥ó¤Ç¡¢»Ä¤ëÌó£²£·£°£°Ëü¿Íʬ¤ò¹ñ»º¤ÇÏŤ¦¤È¤·¤Æ¤¤¤ë¡£
¸üÀ¸Ï«Æ¯¾Ê¤Ï¡¢10·î6Æü¤Ë¡¢¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¡ÊGlaxoSmithKline¡¢GSK¡¢±Ñ¹ñ¡Ë¤È¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¡ÊNovartis Pharmaceuticals Corporation ¡¢¥¹¥¤¥¹¡Ë¤È¤ÎÍ¢Æþ·ÀÌó¤òÄù·ë¤·¤¿¡£
¶¡µëÎ̤ÏGSK¤¬3700Ëü¿Íʬ¡¢¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¤¬1250Ëü¿Íʬ¡¢¹ç·×4950Ëü¿Íʬ¤Ç¤¢¤ë¡£

­¢³¤³°¥ï¥¯¥Á¥ó¤Ë¤Ï¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤ë¥ï¥¯¥Á¥ó¤È¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤Ê¤¤¥ï¥¯¥Á¥ó¤È¤¬¤¢¤ë

³¤³°¥ï¥¯¥Á¥ó(³¤³°À½Â¤¥ï¥¯¥Á¥ó)¤Ë¤Ï¡¢ÌȱÖÊä½õºÞ¡Ê¥¢¥¸¥å¥Ð¥ó¥È¡¢adjuvant¡Ë¤ò»È¤Ã¤Æ¤¤¤ë¥ï¥¯¥Á¥ó¤È¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤Ê¤¤¥ï¥¯¥Á¥ó¤È¤¬¤¢¤ë¡£

¤Þ¤¿¡¢¹ñ¤Ë¤è¤Ã¤Æ¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿¥ï¥¯¥Á¥ó¤ÎºÎÍѤò¤·¤Æ¤¤¤ë¹ñ¤â¤¢¤ì¤Ð¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤Ê¤¤¥ï¥¯¥Á¥ó¤òºÎÍѤ·¤Æ¤¤¤ë¹ñ¤â¤¢¤ë¡£

¤Á¤Ê¤ß¤Ë¡¢¥¢¥á¥ê¥«¤Ç¤Ï¡¢º£²ó¡¢¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤Ë¤Ï¡¢ ¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤Ê¤¤¥ï¥¯¥Á¥ó(unadjuvanted form)¤ò»ÈÍѤ·¤Æ¤¤¤ë¡£

(Ʊ¤¸¥×¥í¥»¥¹¤Ç¡¢¼¡¤Î»Í¼Ò¤ÇÀܼïÂоÝǯÂåÊ̤Ëʬ¤±¤Æºî¤é¤»¤Æ¤¤¤ë¡£
MedImmune LLC(2ºÐ¤«¤é49ºÐ¤Î·ò¹¯¤Ê¿Í¡¢À¸¥ï¥¯¥Á¥ó·ÐÉ¡ÅêÍ¿)¡¢
CSL Limited(18ºÐ°Ê¾å¡¢ÅêÍ¿Î̤ϡ¢0.5 ml )¡¢
Novartis Vaccines and Diagnostics Limited(4ºÐ°Ê¾å¡¢ÅêÍ¿Î̤ϡ¢0.5 ml )¡¢
Sanofi Pasteur Inc(À¸¸å6¥ö·î°Ê¾å¡¢ÅêÍ¿Î̤ϡ¢À¸¸å6¥ö·î¤«¤é35¥ö·î¤Þ¤Ç¤Ï0.25 ml ¡¢»°ºÐ°Ê¾å¤Ï¡¢0.5 ml ).
¤³¤Î¤¦¤Á¡¢MedImmune LLC¤Î¤ß¡¢É¡µÛÆþ¼°¤Î¥Õ¥ë¡¦¥ß¥¹¥È¤È¤¤¤¦Live attenuated ¥ï¥¯¥Á¥ó¡£¸å¤Î»°¼Ò¤ÏÉԳ貽( Inactivated)¥ï¥¯¥Á¥ó
»²¾È¡ÖH1N1 Swine Flu Update¡×)

¤³¤ì¤Ï¡¢¥¢¥á¥ê¥«¹ñÆâ¤Ç»ÈÍѤ¹¤ë¥¢¥¸¥å¥Ð¥ó¥È¤Ï¡¢alum¤È¸Æ¤Ð¤ì¤ë¥¢¥ë¥ß¥Ë¥¦¥à±ö(aluminum salts ¤Þ¤¿¤Ï¡¢Aluminum gels )¤Ë¸ÂÄꤵ¤ì¤Æ¤¤¤ë¤«¤é¤Ç¤¢¤ë¡£¡¡

¸åµ­¤Î¤è¤¦¤Ë¡¢º£²ó¤Î¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¤È¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¤Î¥¢¥¸¥å¥Ð¥ó¥È¤Ï¡¢¥¹¥¯¥ï¥ì¥ó¤ò»È¤Ã¤¿¤â¤Î¤Ç¤¢¤ê¡¢¤³¤Î¥¹¥¯¥ï¥ì¥ó¤ò¥¢¥¸¥å¥Ð¥ó¥È¤Ë»È¤Ã¤¿ÃºÁǶݥ說¥Á¥ó(BioThrax¤ÎAnthrax Vaccine Adsorbed)¤¬¡¢ÏÑ´ßÀïÁè¾É¸õ·²(Gulf War Syndrome-GWS-)¤Î¸¶°ø¤È¤Ê¤Ã¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£
¤³¤Î¤³¤È¤¬¤¢¤Ã¤Æ¡¢¥¢¥á¥ê¥«¤¬¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤Ê¤¤¥ï¥¯¥Á¥ó¤ò»ÈÍѤ¹¤ëÍýͳ¤Î¤è¤¦¤Ç¤¢¤ë¡£
¤³¤ì¤Ï¡¢ÏÑ´ßÀïÁè¤Ë½¾·³¤·¤¿Ê¼»Î¤Ë¤Ï¡¢ÃºÁǶݥ說¥Á¥ó(anthrax vaccines)¤¬½¾·³»þ¤ËÀܼ蘆¤ì¤Æ¤ª¤ê¡¢¤³¤Î¥ï¥¯¥Á¥ó¤Ï¡¢¥¹¥¯¥ï¥ì¥ó¡¦¥Ù¡¼¥¹¤ÎMF59¤ò»ÈÍѤ·¤Æ¤¤¤¿¤¿¤á¡¢¤³¤ì¤é¤ÎÏÑ´ßÀïÁèÂàÌò·³¿Í¤Ë¤Ï¡¢¥¹¥¯¥ï¥ì¥ó¤ËÂФ¹¤ë¹³ÂÎ(anti-squalene antibodies (ASA))¤¬¤¹¤Ç¤Ë¤Ç¤­¤Æ¤¤¤ë¤È¤¤¤ï¤ì¤Æ¤¤¤ë¡£
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Î»²¹Íʸ¸¥¤Ï¡¢¤³¤Á¤é¤Î¥µ¥¤¥È¡ÖSqualene-based adjuvants in vaccines¡×¤´»²¾È
¤Þ¤¿¡¢1976ǯÀܼï¤Ç¤Î¡¢¥®¥é¥ó¥Ð¥ì¡¼¾É¸õ·²ÉûºîÍÑÌäÂêÉâ¾å¤Ø¤Î¥È¥é¥¦¥Þ¤â¤¢¤ë¤è¤¦¤À¡£
»²¹Í¡ÖSwine Flu Vaccine: What The Heck Is an Adjuvant, Anyway?¡×

¤Ê¤ª¡¢¥¤¥®¥ê¥¹¡¢¥«¥Ê¥À¤Ç¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿¥ï¥¯¥Á¥ó¤ò»ÈÍѤ·¤Æ¤¤¤ë¡£
¥Õ¥é¥ó¥¹¤È¥É¥¤¥Ä¤Ï¡¢GSK¼Ò¤Î¥ï¥¯¥Á¥ó¤ò¥Ü¥¤¥³¥Ã¥È¤·¤Æ¤¤¤ë¡£

­£ÆüËܤؤÎÍ¢Æþ¥ï¥¯¥Á¥ó¤Î¥¢¥¸¥å¥Ð¥ó¥È¤Ï¡¢Æó¼Ò°Û¤Ê¤ë¡£

º£²ó¡¢ÆüËܤ¬·ÀÌ󤷤Ƥ¤¤ë¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¡ÊGSK¡¢±Ñ¹ñ¡Ë¤È¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¡Ê¥¹¥¤¥¹¡Ë¤Î¥ï¥¯¥Á¥ó¤Ï¡¢¤¤¤º¤ì¤â¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿¥ï¥¯¥Á¥ó¤òÀ½Â¤¤·¤Æ¤¤¤ë¡£

¤·¤«¤·¡¢Ãí°Õ¤·¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¤Î¤Ï¡¢¤½¤Î¥¢¥¸¥å¥Ð¥ó¥È¤Ï¡¢¥ª¥¤¥ë¡¦¥¤¥ó¡¦¥¦¥©¡¼¥¿¡¼¡¦¥¨¥Þ¥ë¥¸¥ç¥ó(oil-in-water emulsion)¤È¤¤¤¦¥¿¥¤¥×¤Ç¤Ï¶¦Ä̤·¤Æ¤¤¤ë¤â¤Î¤Î¡¢¤½¤Î¥¢¥¸¥å¥Ð¥ó¥È¤Ï¡¢Î¾¼Ò¡¢¤³¤È¤Ê¤ë¤â¤Î¤Ç¤¢¤ë¤È¤¤¤¦¤³¤È¤À¡£

¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¡ÊGSK¡¢±Ñ¹ñ¡Ë¤Ç¤Ï¡¢AS03¤È¤¤¤¦Ì¾¤Î¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤ª¤ê¡¢¤Þ¤¿¡¢¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¡Ê¥¹¥¤¥¹¡Ë¤Ç¤Ï¡¢MF59¤È¤¤¤¦Ì¾¤Î¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤ë¡£

¤Ê¤ª¡¢AS03¤ÈMF59 ¤Î°ã¤¤¤Ï¡¢¼¡¤ÎÀ®Ê¬É½¤ò¤´»²¾È

AS03 (Glaxo-Smith-Kline)
squalene 10.68 mg,
DL–tocopherol (Vitamin E)11.86 mg,
polysorbate 80(Tween80) 4.85 mg

MF59 (Novartis)
squalene 9.75 mg,
polysorbate 80(Tween80) 1.175 mg,
sorbitan trioleate(Span85) 1.175mg

»²¾È¡ÖWhy the epidemiology of swine flu matters¡×

­¤¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤¦¥á¥ê¥Ã¥È

¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤¦¥á¥ê¥Ã¥È¤È¤·¤Æ¤Ï¡¢ÌȱֱþÅúÀ­¤¬¤è¤¯¤Ê¤ë¤È¤¤¤¦ÅÀ¤È¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿À¸»º¥·¥¹¥Æ¥à¤Î¤Û¤¦¤¬¡¢¥ï¥¯¥Á¥óÀ¸»º¤¬Á᤯¡¢¼£¸³¤Ë½½Ê¬¤Ê»þ´Ö¤¬¼è¤ì¤ë¡¢¤È¤¤¤¦2ÅÀ¤¬¡¢ÍøÅÀ¤È¤·¤Æ¤¢¤ë¡£
¤Þ¤¿¡¢WHO¤¬¥ï¥¯¥Á¥ó¥á¡¼¥«¡¼¤ËÂФ·¤Æ¡¢ÌȱֱþÅúÀ­Â¥¿ÊÀïά(antigen sparing strategies)¤òºÎÍѤ»¤è¤È¤ÎÍ×ÀÁ¤¬¤¢¤Ã¤¿¤¿¤á¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»ÈÍѤ·¤Æ¤¤¤ë´ë¶È¤Î»ö¾ð¤¬¤¢¤ë¡£
¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿¥ï¥¯¥Á¥ó¤Ï¡¢ÌȱֱþÅúÀ­¤¬¤¤¤¤¤¿¤á¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤ï¤Ê¤¤¥ï¥¯¥Á¥ó¤ËÈ椷¤Æ¡¢ÌȱÖÈ¿±þ¤ò4Çܲ¡¤·¾å¤²¤ë¤È¤¤¤ï¤ì¤Æ¤¤¤ë¡£
¤Þ¤¿¡¢Ìȱֻý³À­¤â¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤ï¤Ê¤¤¥ï¥¯¥Á¥ó¤ËÈæ¤Ù¤ÆŤ¤¤È¤¤¤ï¤ì¤Æ¤¤¤ë¡£
¤·¤¿¤¬¤Ã¤Æ¡¢º£²ó¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤¬¡¢¹³¸¶¥É¥ê¥Õ¥È¤·¤¿¤ê¤·¤Æ¡¢´¶À÷¤¬Ä¹¤¯Â³¤¯¾ì¹ç¡¢¤³¤Î¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿¥ï¥¯¥Á¥ó¤Î¤Û¤¦¤¬¸ú²Ì¤¬¤¢¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£
¤Ê¤ª¡¢Ä̾ï¤Îµ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤Ë¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤Ê¤¤¤¬¡¢ÇÙ±êµå¶Ý¥ï¥¯¥Á¥ó¤ä¿ñËì±ê¶Ý´¶À÷¾É¥ï¥¯¥Á¥ó¡¢Hib¥ï¥¯¥Á¥ó¤Ê¤É¤Ë¤Ï»È¤ï¤ì¤Æ¤¤¤ë¡£

­¥¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¥ï¥¯¥Á¥ó»ÈÍѤΥ¢¥¸¥å¥Ð¥ó¥È¤ÏAS03¤È¤¤¤¦¤â¤Î

¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¤¬»ÈÍѤ·¤Æ¤¤¤ë¥¢¥¸¥å¥Ð¥ó¥ÈAS03¤Ï¡¢µûÌý¤«¤é¤È¤é¤ì¤¿Í­µ¡²½¹çʪ¤Ç¤¢¤ë¥¹¥¯¥ï¥ì¥ó¤Ë¡¢¿å¤È¥Ó¥¿¥ß¥óE¤È¤òº®¤¼¤¿¤â¤Î¤ò¤Ä¤«¤Ã¤Æ¤¤¤ë¡£
¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¤Ç¤Ï¡¢Ä̾ï¤Îµ¨ÀáÀ­¥ï¥¯¥Á¥óÀ½Â¤¤Ë¤ª¤¤¤Æ¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤Æ¤¤¤Ê¤¤¤¬¡¢º£²ó¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥ï¥¯¥Á¥ó¤ËÀ½Â¤¤ËÅö¤¿¤Ã¤Æ¤Ï¡¢AS03¤È¤¤¤¦Ì¾¤Î¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿¡£
¤½¤ÎÍýͳ¤È¤·¤Æ¡¢º£²ó¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥ï¥¯¥Á¥ó¤Î¾µÇ§¤ËÅö¤¿¤Ã¤Æ¤Ï¡¢°ìÄê¤Î¼£¸³¤ò¾Êά¤·¤¦¤ë” fast-track” ¾µÇ§(Ä̾ï¤Îµ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥óÀ½Â¤¤Ë¤ª¤¤¤Æ¤Ï¡¢¥¦¥¤¥ë¥¹¤Î¥É¥ê¥Õ¥È¤Ê¤É¤Ë¤è¤Ã¤Æ¡¢·ÚÅÙ¤ÎÀ®Ê¬À߷פν¤Àµ¤Ë¤Ä¤¤¤Æ¤Ï¡¢¼£¸³¤¬¾Êά¤·¤¦¤ë¡£)¤¬ÆÀ¤é¤ì¤Ê¤«¤Ã¤¿¤¿¤á¡¢¼£¸³¡¦Î×¾²¼Â¸³¤Ë½½Ê¬¤Ê»þ´Ö¤ò³ä¤¯¤¿¤á¤Ë¤Ï¡¢À¸»º¥¹¥Ô¡¼¥É¤¬Â®¤¤¡¢¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿¥ï¥¯¥Á¥óÀ½Â¤¤ò¤¹¤ëɬÍפ¬¤¢¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
»²¹Í¡ÖFrequently Asked Questions about the swine flu vaccine¡×

A303¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ¤Ï¡¢H5N1Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶Âбþ¥ï¥¯¥Á¥ó¤Î¥Æ¥¹¥È¤Ç¡¢»ÍËü»°Àé¿Í¤Î¥Ü¥é¥ó¥Æ¥£¥¢¤Ë¤è¤ë¥Æ¥¹¥È¤Ç¡¢°ÂÁ´À­¤¬³Îǧ¤µ¤ì¤Æ¤¤¤ë¤È¤¤¤¦¡£

¤Á¤Ê¤ß¤Ë¡¢¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¤Ç¤Ï¡¢¤¹¤Ç¤ËH5N1¥¦¥¤¥ë¥¹(A/Vietnam/1194/2004 NIBRG-14 ¡ÊWHOɸ½à¥ï¥¯¥Á¥ó³ô))¤ÈA303¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿H5N1Âбþ¥ï¥¯¥Á¥ó¡ÖPandemrix¡×( EMEA¾µÇ§)¤òȯÇ䤷¤Æ¤ª¤ê¡¢º£²ó¤Î¥ï¥¯¥Á¥ó¤Ï¡¢¤½¤ì¤Î¥â¥Ã¥¯¥¢¥Ã¥×(mock-up)¥¿¥¤¥×¡ÊÂоݤȤ¹¤ë¥¦¥¤¥ë¥¹³ô¤¬ÆÃÄꤵ¤ì¤Æ¤¤¤Ê¤¤Ãʳ¬¤Ç¡¢¥â¥Ç¥ë¥¦¥¤¥ë¥¹¤òÍѤ¤¤ÆºîÀ½¤µ¤ì¤¿¥ï¥¯¥Á¥ó¡¢À½Â¤¾µÇ§¤Ï¤³¤ÎÃʳ¬¤ÇÆÀ¤Æ¤¤¤ë¡¢¤½¤Ã¤¯¤ê¤µ¤ó¥¿¥¤¥×)¤Ç¤¢¤ë¡¢H1N1¥¦¥¤¥ë¥¹(A/California/7/2009)¤ÈA303¥¢¥¸¥å¥Ð¥ó¥È¤ò»È¤Ã¤¿H1N1ÈÇPandemrix¤È¤¤¤¨¤ë¡£¡¡

­¦¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¥ï¥¯¥Á¥ó¤Ç»ÈÍѤΥ¢¥¸¥å¥Ð¥ó¥È¤ÏMF59¤È¤¤¤¦¤â¤Î

°ìÊý¡¢¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¡Ê¥¹¥¤¥¹¡Ë¤¬»ÈÍѤ·¤Æ¤¤¤ë¥¢¥¸¥å¥Ð¥ó¥ÈMF59¤Ï¡¢¥¹¥¯¥ï¥ì¥ó¡¤³¦Ì̳èÀ­ºÞ¤Î¥Ý¥ê¥½¥ë¥Ù¡¼¥È80¤È0¥½¥ë¥Ó¥¿¥ó¡¦¥È¥ê¥ª¥ì¥¤¥ó»À¡ÊSpan85¡Ë¤ò´Þ¤ó¤Ç¤ª¤ê¡¢¤³¤ì¤é¤òÆý²½¤·¤¿¤â¤Î¤ò0.22¦Ìm¤Î¥Õ¥£¥ë¥¿¡¼¤òÄ̤·¡¤Ä̲ᤷ¤¿Î³»Ò¤Î¤ß¤ò¥¢¥¸¥å¥Ð¥ó¥È¤È¤·¤ÆÍѤ¤¤¿¤â¤Î¤È¤µ¤ì¤Æ¤¤¤ë¡£
MF59¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ¤Ï¡¢¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¡Ê¥¹¥¤¥¹¡Ë¤Ï¡¢¤¹¤Ç¤Ë¡¢ÆüËܤμ¯»ùÅ縩¤Ç·ò¹¯¤ÊÀ®¿ÍÌó£²£°£°¿Í¤ËÎ×¾²»î¸³¡Ê¼£¸³¡Ë¤ò¼Â»Ü¤·¡¢°ÂÁ´À­¤ÈÍ­¸úÀ­¤ò³Îǧ¤·¤Æ¤¤¤ë¤È¤¤¤¦¡£
MF59¥¢¥¸¥å¥Ð¥ó¥È¡¦¥ï¥¯¥Á¥ó¤Î¼£¸³·ë²Ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ÖTrial of Influenza A (H1N1) 2009 Monovalent MF59-Adjuvanted Vaccine — Preliminary Report¡×¤ò¤´»²¾È

¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¤Ë¤ª¤¤¤Æ¤â¡¢¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¤ÎPandemrix ƱÍÍ¡¢¤¹¤Ç¤Ë¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶H5N1Âбþ¤Î¥ï¥¯¥Á¥óFocetria(H5N1)¤òȯÇ䤷¤Æ¤¤¤ë¡£

¤³¤ì¤Ï¡¢Æ±¼Ò¤Îµ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤Î Fluad ¤ÈƱÍͤÎÀ½Â¤¥×¥í¥»¥¹¤Ë¤è¤ë¤â¤Î¤Ç¡¢¥¢¥¸¥å¥Ð¥ó¥È¤Ë¤Ï¡¢½¾Íè¤ÎMF59¤è¤ê¤â°ÂÄêÀ­¤ò¹â¤á¤¿¤È¤µ¤ì¤ëMF59C.1¤ò¡¢¤È¤â¤Ë»È¤Ã¤Æ¤¤¤ë¡£

º£²ó¡¢¤½¤Î¥â¥Ã¥¯¥¢¥Ã¥×(mock-up)¥ï¥¯¥Á¥ó¤È¤·¤Æ¡¢¤³¤ì¤Þ¤Ç¤ÎFocetria(H5N1)¤ò¡¢¥¦¥¤¥ë¥¹¤òA/Vietnam/1194/2004(H5N1)¤«¤éA/California/7/2009 (H1N1)¤ËÆþ¤ìÂؤ¨¤Æ¡¢Focetria(H1N1)¤òÀ½Â¤¤·¤Æ¤¤¤ë¤â¤Î¤Ç¤¢¤ë¡£

­§Tween 80¤ÈSpan85¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ

¥¢¥¸¥å¥Ð¥ó¥È¤Î°ìÉô¤Ë¼õÂ۾㳲ºîÍѤ¬¤¢¤ë¤È·üÇ°¤¹¤ëÀìÌç²È¤¬¤ª¤ê¡¢¡¢¤³¤Î¥¢¥¸¥å¥Ð¥ó¥È¤ò¤Ä¤«¤Ã¤¿¥ï¥¯¥Á¥ó¤ò¼õÂ۾㳲¥ï¥¯¥Á¥ó(Fertility Impairing Vaccine)¤È¤¤¤¦¸þ¤­¤â¤¢¤ë¡£

Tween 80

Polysorbate 80(Tween 80)¤ÈÉÔÇ¥¸¶°øÀâ¤Ë¤Ä¤¤¤Æ¡¢¤³¤Î¥µ¥¤¥È¡ÖSWINE FLU VACCINE INGREDIENTS ¡×¤Ë¼¡¤Î¤è¤¦¤Ë½ñ¤«¤ì¤Æ¤¤¤ë¡£

¡Ö¥Ý¥ê¥½¥ë¥Ù¡¼¥È80¤Ï¡¢Tween 80¤È¤·¤ÆÃΤé¤ì¤Æ¤¤¤ë¤¬¡¢¤³¤ì¤Ï¡¢²½¾ÑÉʤÎÆý²½ºÞ¤È¤·¤Æ»È¤ï¤ì¤Æ¤¤¤ë¤â¤Î¤Ç¤¢¤ë¡£
¤½¤·¤Æ¡¢»ÒµÜðô¤¬¤ó¤Î¥ï¥¯¥Á¥ó¤Î¥¬¡¼¥À¥·¥ë¡ÊGardasil¡Ë¤ÎÀ®Ê¬¤Ç¤â¤¢¤ê¡¢¤³¤ÎGardasil¥ï¥¯¥Á¥ó¤Ï10Âå¤Î½÷À­¤ËÀܼ蘆¤ì¤Æ¤¤¤ë¤â¤Î¤Ç¤¢¤ë¡£
¤³¤ÎÀ®Ê¬¤Ï¡¢ÉÔÇ¥¡¢°­À­Å¾´¹¾ÉáÛÚ»¡¢¼«Á³Î®»º¡¢¤½¤·¤Æ¡¢À¸Ì¿¤Ë¤«¤«¤ï¤ë¥¢¥Ê¥Õ¥£¥é¥­¥·¡¼¡¦¥·¥ç¥Ã¥¯¤òµ¯¤³¤¹¤³¤È¤Ç¤âÃΤé¤ì¤Æ¤¤¤ë¡£
¤³¤ì¤Þ¤Ç¡¢GardasilÀܼï¤Ç¡¢28¿Í¤Î»àË´¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤ë¡£¡×

¤Ê¤ª¡¢polysorbate 80(Tween 80)¤Î¥é¥Ã¥È¤Ë¤è¤ëÉÔÇ¥¼Â¸³¤Ë¤Ä¤¤¤Æ¤Ï¡¢the U.S. Library of Medicine and the National Institute of Health¤«¤é¤ÎÊó¹ð½ñ¡ÖDelayed effects of neonatal exposure to Tween 80 on female reproductive organs in rats.¡×¤¬¤¢¤ë¡£

¤³¤Î¥µ¥¤¥È¡ÖReducing interference between oil-containing adjuvants and surfactant-containing antigens¡×¤Ç¤Ï¡¢
MF59 ¤ÎÀ®Ê¬¤ÎÃæ¤Ç¡¢¥¹¥¯¥¢¥ì¥ó¤¬5¥Ñ¡¼¥»¥ó¥È¡¢polysorbate 80¤¬0.5¥Ñ¡¼¥»¥ó¥È¡¢Span 85¤¬¡¢0.5¥Ñ¡¼¥»¥ó¥È¤¢¤ë¤¬¡¢¤³¤ì¤ò½ÅÎÌ´¹»»¤·¤¿¾ì¹ç¡¢¥¹¥¯¥¢¥ì¥ó4.3¥Ñ¡¼¥»¥ó¥È¡¢polysorbate 80 0.5¥Ñ¡¼¥»¥ó¥È¡¢Span 85¡¡0.48¥Ñ¡¼¥»¥ó¥È¤Ë¤Ê¤ë¤È¤·¤Æ¤¤¤ë¡£

Span85

Ìô¤ä²½¾ÑÉʤäÁ¡°Ý¤ä¥Ú¥¤¥ó¥È¤Ê¤É¤ËÆý²½ºÞ¤È¤·¤Æ¡¢¤Þ¤¿¤Ï¡¢ËÉ»¬ºÞ¤ä¥·¥Ã¥¯¥Ê¡¼¤È¤·¤Æ¡¢»È¤ï¤ì¤ë¡£
»¦ÃîºÞ¤Î°ÂÁ´À­¤òÄɵ᤹¤ëÃÄÂΤǤ¢¤ëPANNA(Pesticide Action Network North America )¤Ë¤è¤ë¤È¡¢¤³¤ÎSpan85¤Ï¡¢»¦ÃîºÞ¤È¤·¤Æ¤â»È¤ï¤ì¤ë¤È¤¤¤¦¡£
Í­¤¹¤ëÆÇÀ­¤È¤·¤Æ¤Ï¡¢È¯¤¬¤óÀ­ÆÇÀ­¡¢À¸¿£ÆÇÀ­¡¢È¯Ã£ÆÇÀ­¡¢¿À·ÐÆÇÀ­¤¬¤¢¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£

»²¹Í¡ÖDangers In The Shots - Components¡¡Of H1N1 Vaccines¡×
¡ÖSqualene Emulsions for Parenteral Vaccine and Drug Delivery¡×¤Î5¥Ú¡¼¥¸¤«¤é11¥Ú¡¼¥¸¤Ë¾Ü¤·¤¤¡£

­¨¥¹¥¯¥ï¥ì¥ó(Squalene)¤ò»ÈÍѤ·¤¿¥¢¥¸¥å¥Ð¥ó¥È¤Î¥ê¥¹¥¯·üÇ°

¤³¤³¤Ç¡¢Î±°Õ¤¹¤Ù¤­¤Ï¡¢¤³¤Îξ¼Ò¤Î¥¢¥¸¥å¥Ð¥ó¥È(MF59¡¢A303)¤È¤â¡¢¥¹¥¯¥ï¥ì¥ó¡¦¥Ù¡¼¥¹¤Î¥ª¥¤¥ë¤ò»È¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¤³¤È¤Ç¤¢¤ë¡£
¥¹¥¯¥ï¥ì¥ó¡¦¥Ù¡¼¥¹¤Î¥ª¥¤¥ë¤¬¡¢¥ê¥ó¥Ñµå¤Ë¹³ÂΤòºî¤ë¤³¤È¤ò»ØÎ᤹¤ëʬ»Ò¡Ö¥¤¥ó ¥¿¡¼¥í¥¤¥­¥ó6¡¢¤Þ¤¿¤Ï¡¢¥¤¥ó¥¿¡¼¥í¥¤¥­¥ó5¡×(Lymphocyte IL-6 ¤Þ¤¿¤ÏIL-5)¤ÎÁý²Ã¤ò¾·¤­¡¢¤³¤ì¤¬¡¢¥µ¥¤¥È¥«¥¤¥ó¸½¾Ý¤ò¾·¤¯¡¢¤È¤Î¸¦µæ¤¬¤¢¤ë¡£
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢AS03¤âMF59¤â¡¢¤È¤â¤Ë¡¢Æ±ÍͤηüÇ°¤¬¤¢¤ë¤Î¤Ç¤Ï¡¢¤È¤Î»ØŦ¤¬¤¢¤ë¤è¤¦¤À¡£
»²¹Í¡ÖConstats corrobor½æPs sur les dangers d½æPmesur½æPs du vaccin H1N1 de Glaxo-Smith-Kline avec l’adjuvant AS03 ¡×

¤Þ¤¿¡¢¤¹¤Ç¤Ë¾åµ­¤Ë½ñ¤¤¤¿¤è¤¦¤Ë¡¢ÏÑ´ßÀïÁè¤Ë½¾·³¤·¤¿Ê¼»Î¤Ë¤Ï¡¢¥¹¥¯¥ï¥ì¥ó¤ò¥¢¥¸¥å¥Ð¥ó¥È¤Ë»È¤Ã¤¿ÃºÁǶݥ說¥Á¥ó(AVIP anthrax vaccine)¤¬½¾·³»þ¤ËÀܼ蘆¤ì¤Æ¤ª¤ê¡¢¤³¤ì¤¬¡¢ÏÑ´ßÀïÁè¾É¸õ·²(Gulf War Syndrome-GWS-)¤Î¸¶°ø¤È¤Ê¤Ã¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£
¤³¤ÎúÁǶݥ說¥Á¥ó¤Ï¡¢¥¹¥¯¥ï¥ì¥ó¡¦¥Ù¡¼¥¹¤ÎMF59¤ò»ÈÍѤ·¤Æ¤¤¤¿¡£
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ÖMillion TIMES More Squalene In H1N1 Vax Than Caused GWI !!¡×
¡ÖANTHRAX VACCINE IMMUNIZATION PROGRAM¡×
¤ò¤´»²¾È

­©Æ°ÊªÍ³Íè¤ÎMDCKÁÈ¿¥¤ò»È¤Ã¤Æ¤ÎÁÈ¿¥ÇÝÍܥ說¥Á¥óÀ½Ë¡¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ¤ÎFDA¤Î·üÇ°ÅÀ

¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¤Î¥ï¥¯¥Á¥ó¤È¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¤Î¥ï¥¯¥Á¥ó¤È¤Ç¤Ï¡¢¥¦¥¤¥ë¥¹ÇÝÍܤβáÄø¤Ç¤ÎÀ½Ë¡¤¬°Û¤Ê¤ë¡£

¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼Ò¤Î¥ï¥¯¥Á¥ó¤Ï¡¢»º¤ßÍî¤È¤µ¤ì¤Æ¤«¤é9¡Ý10Æü¤¿¤Ã¤¿È¯°é·ÜÍñ¡ÊÕÛ²½¤¹¤ë¤Þ¤Ç¤Îȯ°éÅÓ¾å¤Î¾õÂÖ¤ÎÍñ¤ÎÇ¢Ëì¹Ð(allantoic cavity)¤Ç¥¦¥¤¥ë¥¹¤òÁý¿£ÇÝÍܤ¹¤ëÊýË¡¤Î¥ï¥¯¥Á¥ó(embryonated egg culture vaccine)¤Ç¤¢¤ê¡¢
¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¤Î¥ï¥¯¥Á¥ó¤Ï¡¢Æ°ÊªÍ³Íè¤ÎMDCKÁÈ¿¥¤ò»È¤Ã¤ÆÁÈ¿¥ÇÝÍܤ¹¤ëÊýË¡¤Î¥ï¥¯¥Á¥ó(cell culture vaccine)
¤Ç¤¢¤ë¡£

¤³¤Î¸å¼Ô¤Î¥ï¥¯¥Á¥óÀ½Â¤¤Î²áÄø¤Ë¤ª¤±¤ëưʪͳÍè¤ÎÁÈ¿¥ÇÝÍÜ( cell culture )¤Ë¤è¤ëÀ½Ë¡¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ¡¢¥¢¥á¥ê¥«¤ÎFDA¤Ç¤Ï¡¢·üÇ°¤ò¼¨¤·¤Æ¤¤¤ë¡£

ºÙ˦ÇÝÍÜ(culture-based process )¼«ÂΤϡ¢¸Å¤¯¤«¤é¤Îµ»½Ñ¤Ç¤¢¤ë¡£

¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¤Î¥ï¥¯¥Á¥ó¤Ç¤Ï¡¢¿··¿¥¦¥¤¥ë¥¹(A/California/04/2009)¤ò¡¢MDCK(Madin-Darby Canine Kidney)ºÙ˦Æâ¤ÇÁý¿£¤µ¤»¤¿¤â¤Î¤Ë¡¢¾åµ­¤Î¥¢¥¸¥å¥Ð¥ó¥ÈMF59¤òź²Ã¤µ¤»¤Æ¡¢À½Â¤¤·¤Æ¤¤¤ë¡£

MDCKºÙ˦¤Î̾Á°¤Ï¡¢¤â¤È¤â¤È¡¢1958ǯ¤Ë¡¢¥³¥Ã¥«¥¹¥ÑÆ󥨡¼¥ë¤Î¥ª¥¹¤ÎÀ®¸¤(Canine)¤Î¿Õ¡(Kidney)¤òÁÈ¿¥¤È¤·¤Æ¡¢¥«¥ê¥Õ¥©¥ë¥Ë¥¢Âç³Ø¥Ð¡¼¥¯¥ì¡¼¹»¤Î¡¢Madin ¤È Derbyξ»á¤Ë¤è¤Ã¤Æ¡¢³«È¯¤µ¤ì¤¿¤³¤È¤«¤é¡¢¤³¤Î̾Á°¤¬¤Ä¤±¤é¤ì¤Æ¤¤¤ë¡£

º£²ó¤Î¥Î¥Ð¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥Þ¼Ò¤Î¥ï¥¯¥Á¥óÀ½Â¤¤Ï¡¢´ðËÜŪ¤Ë¤Ï¡¢Æ±¼Ò¤Îµ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤Ç¤¢¤ë Optaflu¤ÎÀ½Ë¡¤ò´ð¤Ë¤·¤¿¤â¤Î¤Ç¤¢¤ë¡£

¥¢¥á¥ê¥«FDA¤Ë¤ª¤¤¤Æ¤Ï¡¢MDCKºÙ˦ÇÝÍܤˤè¤ë¥ï¥¯¥Á¥ó¤¬Ì¤¾µÇ§¤Ç¤¢¤ë¡£

¤½¤ÎÍýͳ¤È¤·¤Æ¡¢¤â¤È¤â¤È¤ÎMDCKºÙ˦¤Ë¤Ïȯ´âÀ­ºÙ˦¥ê¥¹¥¯¤Ï¤Ê¤¤¤¬¡¢MDCKºÙ˦¤Î²½³ØŪ¤Ë·Á¤òÊѤ¨¤¿Í¶Æ³ÂÎ(chemically transformed derivative)¤Ç¤¢¤ëMDCK-T1¤Ëȯ´âÀ­ºÙ˦¥ê¥¹¥¯(¼ðá縶À­-tumorigenicity-)¤¬¤¢¤ê¤¦¤ë¤È¤·¤Æ¡¢
A.DNA(Residual DNA)¤Î¥³¥ó¥¿¥ß¥Í¡¼¥·¥ç¥ó¤¬¤¢¤ë¤«?
¥ï¥¯¥Á¥ó¤ÎºÇ½ªÀ½ÉʤβáÄø¤Ë¤ª¤¤¤Æ¡¢¤¹¤Ù¤Æ¤ÎºÙ˦¤¬¼è¤ê½ü¤«¤ì¤ë¤¿¤á¤Î¡¢¥Õ¥£¥ë¥¿¥ê¥ó¥°µ»½Ñ¤Î³ÎΩ¤¬É¬ÍפǤ¢¤ë¡£
MDCKºÙ˦¤Ï¡¢¸¤¤ÎÁÈ¿¥¤Ç¤¢¤ë¤¬¡¢¥ï¥¯¥Á¥óÃí¼Í¤Ë¤è¤Ã¤Æ¡¢¿Í¤È¸¤¤È¤ÎDNA(Residual DNA)¤Î¥³¥ó¥¿¥ß¥Í¡¼¥·¥ç¥ó¤¬¤¢¤ë¤«?
B.¶öȯŪ¤Êɸ¶ÂΤΥ³¥ó¥¿¥ß¥Í¡¼¥·¥ç¥ó¤¬¤¢¤ë¤«?
C.¥¦¥¤¥ë¥¹¤ÈºÙ˦¤È¤ÎÀøºßŪ¤ÊÁê¸ßºîÍѤ¬¤¢¤ë¤«?
¤Ê¤É¤ò¡¢FDA¤Ï´í×ü¤·¤Æ¤¤¤ë¤è¤¦¤Ç¤¢¤ë¡£
¤³¤ÎÅÀ¤Ë¤Ä¤¤¤Æ¤ÎFDA¤Î¸«²ò¤Ï¡¢
¡ÖFDA: Use of MDCK Cells for Manufacture of Inactivated Influenza vaccines¡×
¡Ö¡ÈDesigner¡É1 Cells as Substrates¡¡for the Manufacture of Viral Vaccines¡×
¤ò¤´»²¾È

»²¹Í¡ÖUse of Madin-Darby Canine Kidney (MDCK) Cells for Manufacture of Inactivated Influenza Vaccines¡×

¤¿¤À¡¢FDA¼«ÂΤ⡢ºÙ˦ÇÝÍÜ(culture-based process )¤Ë¤è¤ë¥ï¥¯¥Á¥óÀ½Â¤¤ÎÍøÅÀ¤Ë¤Ä¤¤¤Æ¤Ï¡¢Ç§¼±¤ò¼¨¤·¤Æ¤¤¤ë¤è¤¦¤Ç¤¢¤ë¡£

Æäˡ¢¡Ö¸ø¶¦¶ÛµÞ»öÂÖ½àÈ÷Ë¡¡×(The Public Readiness and Emergency Preparedness Act (¡ÈPREP Act¡É) ¤ÎÀ®Î©¤Ë¤è¤Ã¤Æ¡¢¸Ä¿Í¤Î¥ï¥¯¥Á¥óÈï³²¤Ø¤ÎÊä½þ¤¬²Ì¤¿¤µ¤ì¡¢¹ñ¤ä¥ï¥¯¥Á¥ó¥á¡¼¥«¡¼¤ÎÉÔË¡¹Ô°ÙÇå½þÀÕǤ(Tort Liability)¤Ø¤ÎÌÈÀÕ¤¬¿Þ¤é¤ì¤ë¤È¤¤¤¦Ë¡À©ÅٴĶ­¤ÎÊѲ½¤¬¡¢FDA¤ò¤·¤Æ¡¢½ÀÆð¤ÊÂбþ¤Ø¤Î¥·¥Õ¥È¤ò¤µ¤»¤Æ¤¤¤ë¤â¤Î¤È»×¤ï¤ì¤ë¡£

¿·¤·¤¤¥ï¥¯¥Á¥óÀ½Â¤µ»½Ñ¤Îɾ²Á¤Ë¤Ä¤¤¤Æ¤Ï
¡ÖA New Vaccine Supply Strategy ¡×
¡ÖFlu Vaccines and the Risk of Cancer ¡×
¡ÖWhat You Need to Know About the New Flu Shots ¡×
¤Ê¤É¤ò¤´»²¾È

­ª¥¢¥á¥ê¥«»ÈÍѤÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¡¦¥ï¥¯¥Á¥ó¤Î¥Á¥á¥í¥µ¡¼¥ë¤È¿å¶ä¤Î´ÞÍ­ÎÌ°ìÍ÷

CSL Limited
¥Á¥á¥í¥µ¡¼¥ë¡¡0.01%(1:10000)
¿å¶ä¡¡24.5 mcg/0.5ml

Novartis Vaccines and Diagnostics Limited
¥Á¥á¥í¥µ¡¼¥ë¡¡0.01%(1:10000)
¿å¶ä¡¡25¡¡mcg/0.5ml

Sanofi Pasteur Inc
¥Á¥á¥í¥µ¡¼¥ë¡¡0.01%(1:10000)
¿å¶ä¡¡25 mcg/0.5ml

MedImmune LLC
¥Á¥á¥í¥µ¡¼¥ë¡¡0%(1:10000)
¿å¶ä¡¡0 mcg/0.5ml

Ç»ÅÙ¡¡1:10,000
= 0.01% Ç»ÅÙ
= 50 ¥Þ¥¤¥¯¥í¥°¥é¥à/0.5 mL ¤¢¤¿¤ê

1 ¥Þ¥¤¥¯¥í¥°¥é¥à

= 1mcg
= 1¥°¥é¥à¤ÎÉ´Ëüʬ¤Î°ì

¾®»ùÍѥ說¥Á¥ó¤Î¤Û¤È¤ó¤É¤Ï¡¢0.5 mL (¥ß¥ê¥ê¥Ã¥È¥ë¤ÎȾʬ)¤ÇÄ󶡤µ¤ì¤ë¡£
¤·¤¿¤¬¤Ã¤Æ¡¢Ç»Å٤ΤۤȤó¤É¤Ï¡¢”per 0.5 mL.” ¤ÇÊó¹ð¤µ¤ì¤Æ¤¤¤ë¡£

¥Á¥á¥í¥µ¡¼¥ë¤ÎȾʬ¤Ï¡¢¿å¶ä¤Ê¤Î¤Ç¡¢

¥Á¥á¥í¥µ¡¼¥ëÇ»ÅÙ0.01%¤Î¥ï¥¯¥Á¥ó
= 0.005% ¿å¶äÇ»ÅÙ
= 25 ¥Þ¥¤¥¯¥í¥°¥é¥à¤Î¿å¶ä¡¿¥ï¥¯¥Á¥ó0.5mL¤¢¤¿¤ê

(¤Á¤Ê¤ß¤Ë¡¢
¿©Âî¤Ë¶¡¤µ¤ì¤ëµû¤ÎÊ¿¶Ñ¿å¶ä´ÞÍ­ÎÌ¡á23¥Þ¥¤¥¯¥í¥°¥é¥à¡¿µû8¥ª¥ó¥¹¤¢¤¿¤ê
8¥ª¥ó¥¹¡á226796185¥Þ¥¤¥¯¥í¥°¥é¥à¡á226¥°¥é¥à

µû1¥°¥é¥à¤¢¤¿¤ê¤Ç¤Ï¡¢
23¡à226¡á0.10¥Þ¥¤¥¯¥í¥°¥é¥à)

»²¹Í¡ÖThimerosal Content in Some US Licensed Vaccines¡×

¤½¤Î¾¤Î¹½À®À®Ê¬¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È¡ÖComponents of¡¡H1N1 Influenza A Vaccines 2009/10¡×¤ò¤´»²¾È

°Ê¾å

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/10/30 Friday

¡Ö¥ï¥¯¥Á¥óÀܼï¤Ï°ì²ó¡×¤È¤ÎWHOÀìÌç²È¥°¥ë¡¼¥×¤Î´«¹ð³µÌõ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 23:10:55

2009ǯ10·î30Æü
¡¡
ËÜÆü¡¢WHO¤«¤éȯɽ¤µ¤ì¤¿
¡ÖExperts advise WHO on pandemic vaccine policies and strategies¡×
¤Î³µÌõ¤Ç¤¹¡£

WHO¤ÎÌȱֲ½¤Ë´Ø¤¹¤ëÀïάŪ´«¹ðÀìÌç²È¥°¥ë¡¼¥×(SAGE)¤Ï¡¢10·î27Æü¤«¤é29Æü¤Ë¤ï¤¿¤Ã¤Æ²ñµÄ¤ò¤Ò¤é¤­¡¢ ¸½ºß¤Ë¤ª¤±¤ëÀ¤³¦¤Î´¶À÷ή¹Ô¤Î±Ö³ØŪ¾õ¶·¤Ë¤Ä¤¤¤ÆºÆ¸¡Æ¤¤·¡¢¸ø½°±ÒÀ¸Åª¤Ê´ÑÅÀ¤«¤é¤ÎÌäÂê¤ò¹Íθ¤·¤¿¡£

¤½¤³¤Ç¤Ï¡¢¥ï¥¯¥Á¥ó¤ÎÌȱָ¶À­¤Ë¤Ä¤¤¤Æ¤ÎÎ×¾²¼Â¸³¤«¤é¤ß¤Æ¤Î¥ï¥¯¥Á¥óÀܼï¤Î²Äǽ¤Ê¾õ¶·¤ä¡¢¸½ºßÀܼïÃæ¤Î¹ñ¡¹¤Ë¤ª¤±¤ë°ÂÁ´À­¤Î¥â¥Ë¥¿¥ê¥ó¥°¤Ë¤Ä¤¤¤Æ¤Î®Êó·ë²Ì¤Ê¤É¤Ë¤Ä¤¤¤Æ¡¢µÄÂê¤È¤·¤¿¡£

Ʊ»þ¤Ë¡¢¥¦¥¤¥ë¥¹¤«¤é¤ÎËɸæ¤ËɬÍפÊÀܼï²ó¿ô¤Ë¤Ä¤¤¤Æ¤ä¡¢¤³¤È¤Ê¤Ã¤¿Ç¯ÎðÁؤˤª¤±¤ëµ¨ÀáÀ­¤È¿··¿¤È¤Î¥ï¥¯¥Á¥ó¤È¤ÎƱ»þÀܼï¤ä¡¢Ç¥ÉؤؤΥ說¥Á¥óÀܼï¤ÎÌäÂê¤Ë¤Ä¤¤¤Æ¤âµÄÂê¤È¤·¤¿¡£

¤µ¤é¤Ë¡¢2010ǯ¤Ë¤ª¤±¤ëÆîȾµå¤Ç¤Îµ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤Î¿ä¾©¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥óÀ½Â¤³ô¤Î¹½À®¤Ë¤Ä¤¤¤Æ¤â¡¢µÄÂê¤È¤·¤¿¡£

­¡¸½ºß¤Î¾õ¶·

À¤³¦¤Î¸½¾õ¤Ï¡¢¥Æ¥£¡¼¥ó¥¨¡¼¥¸¥ã¡¼¤ä¥ä¥ó¥°¥¢¥À¥ë¥È¤Î´¶À÷¤¬°ÍÁ³¤È¤·¤ÆÁý²Ã¤·Â³¤±¤Æ¤ª¤ê¡¢¤Þ¤¿¡¢ÆýÍÄ»ù¤ÎÆþ±¡Î¨¤âÁý²Ã¤·¤Æ¤¤¤ë¡£

´µ¼Ô¤Î1¥Ñ¡¼¥»¥ó¥È¤«¤é10¥Ñ¡¼¥»¥ó¥È¤¬¡¢Æþ±¡¤ò ɬÍפȤ·¤Æ¤¤¤ë¾õ¶·¤Ç¤¢¤ë¡£

¤Þ¤¿¡¢Æþ±¡¤·¤¿´µ¼Ô¤Î10¥Ñ¡¼¥»¥ó¥È¤«¤é25¥Ñ¡¼¥»¥ó¥È¤¬¡¢½¸Ãæ¼£Îż¼¤Ø¤ÎÆþ¼¼¤òɬÍפȤ¹¤ë¾õ¶·¤Ç¤¢¤ë¡£

¤½¤Î¤¦¤Á¤Î2¥Ñ¡¼¥»¥ó¥È¤«¤é9¥Ñ¡¼¥»¥ó¥È¤¬½Å¾É¤Ç¤¢¤ë¡£

¤¹¤Ù¤Æ¤ÎÆþ±¡¼Ô¤Î7¥Ñ¡¼¥»¥ó¥È¤«¤é10¥Ñ¡¼¥»¥ó¥È¤¬Ç¥ÉؤǤ¢¤ê¡¢°ìÈ̿ͤÈÈæ³Ó¤¹¤ë¤È¡¢Ç¥Éؤϡ¢¤½¤Î10ÇÜ¡¢½¸Ãæ¼£Îż¼¤Ç¤Î´Ç¸î¤òɬÍפȤ¹¤ë¾õ¶·¤Ç¤¢¤ë¡£

¤³¤Î¤è¤¦¤Ê¸½ºß¤Î¾õ¶·¤òƧ¤Þ¤¨¡¢ ÀìÌç²È¤Ï¡¢°Ê²¼¤Î´«¹ð¤ò¤¹¤ë¡£

­¢¥ï¥¯¥Á¥óÀܼï¤Ï¡¢°ì²ó¤ò¿ä¾©¤¹¤ë

¸½ºßǧ²Ä¤µ¤ì¤Æ¤¤¤ë¥ï¥¯¥Á¥ó¤Ë¤Ä¤¤¤Æ¡¢¤½¤ì¤¬¡¢À¸¤Ç¤¢¤í¤¦¤È¡¢ÉԳ貽¤Ç¤¢¤í¤¦¤È¡¢¥¢¥¸¥å¥Ð¡¬¥ó¥ÈÆþ¤ê¤Ç¤¢¤í¤¦¤È¤Ê¤«¤í¤¦¤È¡¢´ÆÆĵ¡´Ø¤«¤é¤Î»Ø¼¨¤¬°ìÃפ·¤Æ¤¤¤ë¾ì¹ç¤Ë¤Ï¡¢10ºÐ°Ê¹ß¤ÎÀ®¿Í¡¦ÀÄǯ¤Ø¤ÎÀܼï¤Ï¡¢°ì²óÀܼï¤ò¿ä¾©¤¹¤ë¡£

À¸¸å6¥ö·î¤«¤é10ºÐ°Ê²¼¤Î»Ò¤É¤â¤Ë¤Ä¤¤¤Æ¤Ï¡¢Ìȱָ¶À­¥Ç¡¼¥¿¤¬¸Â¤é¤ì¤Æ¤ª¤ê¡¢¹¹¤Ê¤ë¸¦µæ¤¬É¬ÍפǤ¢¤ë¡£

¹ñ¤¬»Ò¶¡¤¿¤Á¤ËÍ¥ÀèÀܼï½ç°Ì¤ò ÃÖ¤¤¤Æ¤¤¤ë¹ñ¤Ë¤ª¤¤¤Æ¤Ï¡¢¤Ç¤­¤ë¤À¤±Â¿¤¯¤Î»Ò¤É¤â¤¿¤Á¤Ë¥ï¥¯¥Á¥óÀܼ郎¤¤¤­¤ï¤¿¤ë¤è¤¦¤Ë¡¢°ì²óÀܼï¤ò¿ä¾©¤¹¤ë¡£

¤Ê¤ª¡¢Ìȱ־㳲¤ò»ý¤Ä¿Í¡¹¤ËÂФ·¤Æ¤Ï¡¢¤½¤ÎÅêÍ¿ÎÌÇ¡²¿¤Ë¤Ä¤¤¤Æ¡¢¹¹¤Ê¤ë¸¦µæ¤¬É¬ÍפǤ¢¤ë¤È¤¤¤¦¤³¤È¤ò¶¯Ä´¤·¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¡£

­£µ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤È¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤ÎƱ»þÅêÍ¿¤Ë¤Ä¤¤¤Æ

µ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤È¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤ÎƱ»þÅêÍ¿¤Ë¤Ä¤¤¤Æ¤Ï¡¢Î×¾²¼Â¸³¤¬¿Ê¹ÔÃæ¤Ç¤¢¤ë¤¬¡¢CDC¤Î¸«²ò¤Ç¤Ï¡¢¼åÆDz½¤·¤¿À¸¥ï¥¯¥Á¥ó¤Ë¤Ä¤¤¤Æ¤Ï¡¢Æ±»þÅêÍ¿¤ÏÈò¤±¤ë¤Ù¤­¤Ç¤¢¤ë¡¢¤È¤·¤Æ¤¤¤ë¡£

µ¨ÀáÀ­¡¦¿··¿Î¾Êý¤Î¥ï¥¯¥Á¥ó¤¬ÉԳ貽¥ï¥¯¥Á¥ó¤Ç¤¢¤Ã¤¿¤ê¡¢ÊÒÊý¤Î¤ßÀ¸¥ï¥¯¥Á¥ó¤Ç¤¢¤Ã¤¿¾ì¹ç¤Ç¤Ï¡¢Æ±»þÅêÍ¿¤Ïµö¤µ¤ì¤ë¡£

¤³¤Î¤è¤¦¤Ê¾ì¹ç¤ÎƱ»þÅêÍ¿¤Ç¤Ï¡¢Í­³²»ö¾Ý¤Î¥ê¥¹¥¯¤òÁýÂ礵¤»¤ë¾Úµò¤Ï¡¢¤Ê¤ó¤é¸«Åö¤¿¤é¤Ê¤¤¡£

¥ï¥¯¥Á¥ó¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤ì¤Þ¤Ç¥ï¥¯¥Á¥óÀܼ路¤¿¤â¤Î¤Ë¤Ä¤¤¤Æ¤Î¥â¥Ë¥¿¡¼¤Ç¤Ï¡¢°Û¾ï¤ÊÉûºîÍÑ(ÉûÈ¿±þ)¤Ï¸«¤é¤ì¤Æ¤¤¤Ê¤¤¡£

¤¤¤¯¤Ä¤«¤ÎÉûºîÍÑ(ÉûÈ¿±þ)Îã¤Ï¡¢¤¢¤ë¤¬¡¢¤½¤ì¤é¤Ï¡¢µ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥óÅêÍ¿¤Ç¸«¤é¤ì¤ëÈϰϤΤâ¤Î¤Ë¤È¤É¤Þ¤Ã¤Æ¤¤¤ë¡£

¸½ºß¤Î¤È¤³¤í¤Ï¡¢°ÂÁ´À­¤Ï³Îǧ¤µ¤ì¤Æ¤¤¤ë¤¬¡¢°ú¤­Â³¤­¥â¥Ë¥¿¡¼¤Ï³¤±¤ë¡£

­¤Ç¥ÉؤؤΥ說¥Á¥óÅêÍ¿¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ

Ç¥ÉؤؤΥ說¥Á¥ó¤Ë¤Ä¤¤¤Æ¡¢¼Â¸³Æ°Êª¤Ø¤ÎÀ¸¼åÆDz½¥ï¥¯¥Á¥ó¤ÎÅêÍ¿¤Ç¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥È¤Î¤¢¤ë¤Ê¤·¤Ë¤«¤«¤ï¤é¤º¡¢¼õÂÛǽÎÏ,Ç¥¿±¡¢ÂÛ²ê¤Îȯã¡¢ÂÛ»ù¤Îȯã¤ËÂФ·¤Æ¤Î¡¢Ä¾ÀÜŪ¡¦´ÖÀÜŪ±Æ¶Á¤Ï¸«¤é¤ì¤Æ¤¤¤Ê¤¤¡£

¤³¤ì¤é¤Î¤³¤È¤«¤é¡¢ÆÃÄê¤Î¶Ø´÷¾É¾õ¤¬³Îǧ¤µ¤ì¤Ê¤¤¸Â¤ê¡¢Ç§²Ä¤µ¤ì¤¿¥ï¥¯¥Á¥ó¤Ç¤¢¤ì¤Ð¡¢Ç¥ÉؤؤΥ說¥Á¥ó»ÈÍѤϲÄǽ¤Ç¤¢¤ë¡£

­¥2010ǯ¤ÎÆîȾµå¤Ç¤Î¿ä¾©¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥óÀ½Â¤³ô¤Î¹½À®¤Ë¤Ä¤¤¤Æ

Æó¤Ä¤Î¥ª¥×¥·¥ç¥ó¤Ë¤Ä¤¤¤Æ¡¢¸¡Æ¤¤µ¤ì¤¿¡£

¤Ò¤È¤Ä¤Ï¡¢»°²Á¥ï¥¯¥Á¥ó(H1N1.H3N2.B·¿)¡¢
¤â¤¦¤Ò¤È¤Ä¤Ï¡¢Æó²Á¥ï¥¯¥Á¥ó(H3N2.B·¿)¤Ç¤¢¤ë¡£

¸å¼Ô¤Ë¤Ä¤¤¤Æ¤Ï¡¢¸½ºß¤Î¿··¿H1N1¥ï¥¯¥Á¥ó¤òÊ䤦·Á¤Ç¤ÎÀܼï¤È¤Ê¤ë¡£

ÀìÌç²È¥°¥ë¡¼¥×¤È¤·¤Æ¤Ï¡¢Î¾¼Ô¤Î¥ª¥×¥·¥ç¥ó¤È¤â²Äǽ¤ÊÁªÂò¤Ç¤¢¤ë¡¢¤È¤¹¤ë¡£

°Ê¾å

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

º£Æü¡Ö¥ï¥¯¥Á¥óÀܼï°ì²ó¡×¤ò¿ä¾©¤·¤¿WHOÀìÌç²È¥°¥ë¡¼¥×¤ÎÊó¹ð½ñ³µÌõ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 22:54:40

2009ǯ10·î30Æü
¡¡
ËÜÆü¡¢WHO¤«¤éȯɽ¤µ¤ì¤¿
¡ÖExperts advise WHO on pandemic vaccine policies and strategies¡×
¤Î³µÌõ¤Ç¤¹¡£

WHO¤ÎÌȱֲ½¤Ë´Ø¤¹¤ëÀïάŪ´«¹ðÀìÌç²È¥°¥ë¡¼¥×(SAGE)¤Ï¡¢10·î27Æü¤«¤é29Æü¤Ë¤ï¤¿¤Ã¤Æ²ñµÄ¤ò¤Ò¤é¤­¡¢ ¸½ºß¤Ë¤ª¤±¤ëÀ¤³¦¤Î´¶À÷ή¹Ô¤Î±Ö³ØŪ¾õ¶·¤Ë¤Ä¤¤¤ÆºÆ¸¡Æ¤¤·¡¢¸ø½°±ÒÀ¸Åª¤Ê´ÑÅÀ¤«¤é¤ÎÌäÂê¤ò¹Íθ¤·¤¿¡£

¤½¤³¤Ç¤Ï¡¢¥ï¥¯¥Á¥ó¤ÎÌȱָ¶À­¤Ë¤Ä¤¤¤Æ¤ÎÎ×¾²¼Â¸³¤«¤é¤ß¤Æ¤Î¥ï¥¯¥Á¥óÀܼï¤Î²Äǽ¤Ê¾õ¶·¤ä¡¢¸½ºßÀܼïÃæ¤Î¹ñ¡¹¤Ë¤ª¤±¤ë°ÂÁ´À­¤Î¥â¥Ë¥¿¥ê¥ó¥°¤Ë¤Ä¤¤¤Æ¤Î®Êó·ë²Ì¤Ê¤É¤Ë¤Ä¤¤¤Æ¡¢µÄÂê¤È¤Ê¤Ã¤¿¡£

Ʊ»þ¤Ë¡¢¥¦¥¤¥ë¥¹¤«¤é¤ÎËɸæ¤ËɬÍפÊÀܼï²ó¿ô¤Ë¤Ä¤¤¤Æ¤ä¡¢¤³¤È¤Ê¤Ã¤¿Ç¯ÎðÁؤˤª¤¤¤Æ¡¢µ¨ÀáÀ­¤È¿··¿¤È¤Î¥ï¥¯¥Á¥ó¤Î¤ÈƱ»þÀܼï¤äÇ¥ÉؤؤΥ說¥Á¥óÀܼï¤ÎÌäÂê¤Ë¤Ä¤¤¤Æ¤âµÄÂê¤È¤Ê¤Ã¤¿¡£

¤µ¤é¤Ë¡¢2010ǯ¤Ë¤ª¤±¤ëÆîȾµå¤Ç¤Îµ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤Î¿ä¾©¹½À®³ô¤Ë¤Ä¤¤¤Æ¤â¡¢µÄÂê¤È¤Ê¤Ã¤¿¡£

­¡¸½ºß¤Î¾õ¶·

À¤³¦¤Î¸½¾õ¤Ï¡¢¥Æ¥£¡¼¥ó¥¨¡¼¥¸¥ã¡¼¤ä¥ä¥ó¥°¥¢¥À¥ë¥È¤Î´¶À÷¤¬°ÍÁ³¤È¤·¤ÆÁý²Ã³¤±¤Æ¤ª¤ê¡¢¤Þ¤¿¡¢ÆýÍÄ»ù¤ÎÆþ±¡Î¨¤âÁý²Ã¤·¤Æ¤¤¤ë¡£

´µ¼Ô¤Î1¥Ñ¡¼¥»¥ó¥È¤«¤é10¥Ñ¡¼¥»¥ó¥È¤¬¡¢Æþ±¡¤ò ɬÍפȤ·¤Æ¤¤¤ë¾õ¶·¤Ç¤¢¤ë¡£

¤Þ¤¿¡¢Æþ±¡¤·¤¿´µ¼Ô¤Î10¥Ñ¡¼¥»¥ó¥È¤«¤é25¥Ñ¡¼¥»¥ó¥È¤¬¡¢½¸Ãæ¼£Îż¼¤Ø¤ÎÆþ¼¼¤òɬÍפȤ¹¤ë¾õ¶·¤Ç¤¢¤ë¡£

¤½¤Î¤¦¤Á¤Î2¥Ñ¡¼¥»¥ó¥È¤«¤é9¥Ñ¡¼¥»¥ó¥È¤¬½Å¾É¤Ç¤¢¤ë¡£

¤¹¤Ù¤Æ¤ÎÆþ±¡¼Ô¤Î7¥Ñ¡¼¥»¥ó¥È¤«¤é10¥Ñ¡¼¥»¥ó¥È¤¬Ç¥ÉؤǤ¢¤ê¡¢°ìÈ̿ͤÈÈæ³Ó¤¹¤ë¤È¡¢Ç¥Éؤϡ¢¤½¤Î10ÇÜ¡¢½¸Ãæ¼£Îż¼¤Ç¤Î´Ç¸î¤òɬÍפȤ¹¤ë¾õ¶·¤Ç¤¢¤ë¡£

¤³¤Î¤è¤¦¤Ê¸½ºß¤Î¾õ¶·¤òƧ¤Þ¤¨¡¢ ÀìÌç²È¤Ï¡¢°Ê²¼¤Î´«¹ð¤ò¤¹¤ë¡£

­¢¥ï¥¯¥Á¥óÀܼï¤Ï¡¢°ì²ó¤ò¿ä¾©¤¹¤ë

¸½ºßǧ²Ä¤µ¤ì¤Æ¤¤¤ë¥ï¥¯¥Á¥ó¤Ë¤Ä¤¤¤Æ¡¢¤½¤ì¤¬¡¢À¸¤Ç¤¢¤í¤¦¤È¡¢ÉԳ貽¤Ç¤¢¤í¤¦¤È¡¢¥¢¥¸¥å¥Ð¡¬¥ó¥ÈÆþ¤ê¤Ç¤¢¤í¤¦¤È¤Ê¤«¤í¤¦¤È¡¢´ÆÆĵ¡´Ø¤«¤é¤Î»Ø¼¨¤¬°ìÃפ·¤Æ¤¤¤ë¾ì¹ç¤Ë¤Ï¡¢10ºÐ°Ê¹ß¤ÎÀ®¿Í¡¦ÀÄǯ¤Ø¤ÎÀܼï¤Ï¡¢°ì²óÀܼï¤ò¿ä¾©¤¹¤ë¡£

À¸¸å6¥ö·î¤«¤é10ºÐ°Ê²¼¤Î»Ò¤É¤â¤Ë¤Ä¤¤¤Æ¤ÎÌȱָ¶À­¥Ç¡¼¥¿¤¬¸Â¤é¤ì¤Æ¤ª¤ê¡¢¹¹¤Ê¤ë¸¦µæ¤¬É¬ÍפǤ¢¤ë¡£

¹ñ¤¬»Ò¶¡¤¿¤Á¤ËÍ¥ÀèÀܼï½ç°Ì¤ò ÃÖ¤¤¤Æ¤¤¤ë¹ñ¤Ë¤ª¤¤¤Æ¤Ï¡¢¤Æ¡¬¤­¤ë¤À¤±Â¿¤¯¤Î»Ò¤É¤â¤¿¤Á¤Ë¥ï¥¯¥Á¥óÀܼ郎¤¤¤­¤ï¤¿¤ë¤è¤¦¤Ë¡¢°ì²óÀܼï¤ò¿ä¾©¤¹¤ë¡£
¤Ê¤ª¡¢Ìȱ־㳲¤ò»ý¤Ä¿Í¡¹¤ËÂФ·¤Æ¤Ï¡¢¤½¤ÎÅêÍ¿ÎÌÇ¡²¿¤Ë¤Ä¤¤¤Æ¡¢¹¹¤Ê¤ë¸¦µæ¤¬É¬ÍפǤ¢¤ë¤È¶¯Ä´¤·¤Æ¤¤¤ë¡£

­£µ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤È¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤ÎƱ»þÅêÍ¿¤Ë¤Ä¤¤¤Æ

µ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤È¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤ÎƱ»þÅêÍ¿¤Ë¤Ä¤¤¤Æ¤Ï¡¢Î×¾²¼Â¸³¤¬¿Ê¹ÔÃæ¤Ç¤¢¤ë¤¬¡¢CDC¤Î¸«²ò¤Ç¤Ï¡¢¼åÆDz½¤·¤¿À¸¥ï¥¯¥Á¥ó¤Ë¤Ä¤¤¤Æ¤Ï¡¢Æ±»þÅêÍ¿¤ÏÈò¤±¤ë¤Ù¤­¤Ç¤¢¤ë¤È¤·¤Æ¤¤¤ë¡£

µ¨ÀáÀ­¡¦¿··¿Î¾Êý¤Î¥ï¥¯¥Á¥ó¤¬ÉԳ貽¥¯¥Á¥ó¤Ç¤¢¤Ã¤¿¤ê¡¢ÊÒÊý¤Î¤ßÀ¸¥ï¥¯¥Á¥ó¤Ç¤¢¤Ã¤¿¾ì¹ç¤Ç¤Ï¡¢Æ±»þÅêÍ¿¤Ïµö¤µ¤ì¤ë¡¢¤È¤·¤Æ¤¤¤ë¡£

¤³¤Î¤è¤¦¤Ê¾ì¹ç¤ÎƱ»þÅêÍ¿¤Ç¤Ï¡¢Í­³²»ö¾Ý¤Î¥ê¥¹¥¯¤òÁýÂ礵¤»¤ë¾Úµò¤Ï¡¢¤Ê¤ó¤é¸«Åö¤¿¤é¤Ê¤¤¡¢¤È¡¢¤·¤Æ¤¤¤ë¡£
¡¡¥ï¥¯¥Á¥ó¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤ì¤Þ¤Ç¥ï¥¯¥Á¥óÀܼ路¤¿¤â¤Î¤Ë¤Ä¤¤¤Æ¤Î¥â¥Ë¥¿¡¼¤Ç¤Ï¡¢°Û¾ï¤ÊÉûºîÍѤϸ«¤é¤ì¤Æ¤¤¤Ê¤¤¡£

¤¤¤¯¤Ä¤«¤ÎÉûºîÍÑÎã¤Ï¡¢¤¢¤ë¤¬¡¢¤½¤ì¤é¤Ï¡¢µ¨ÀáÀ­¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥óÅêÍ¿¤Ç¸«¤é¤ì¤ëÈϰϤΤâ¤Î¤Ë¤È¤É¤Þ¤Ã¤Æ¤¤¤ë¡£

¸½ºß¤Î¤È¤³¤í¤Ï¡¢°ÂÁ´À­¤Ï³Îǧ¤µ¤ì¤Æ¤¤¤ë¤¬¡¢°ú¤­Â³¤­¥â¥Ë¥¿¡¼¤Ï³¤±¤ë¡£

­¤Ç¥ÉؤؤΥ說¥Á¥óÅêÍ¿¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ

Ç¥ÉؤؤΥ說¥Á¥ó¤Ë¤Ä¤¤¤Æ¡¢¼Â¸³Æ°Êª¤Ø¤ÎÀ¸¼åÆDz½¥ï¥¯¥Á¥ó¤ÎÅêÍ¿¤Ç¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥È¤Î¤¢¤ë¤Ê¤·¤Ë¤«¤«¤ï¤é¤º¡¢¼õÂÛǽÎÏ,Ç¥¿±¡¢ÂÛ²ê¤Îȯã¡¢ÂÛ»ù¤Îȯã¤ËÂФ·¤Æ¤Î¡¢Ä¾ÀÜŪ¡¦´ÖÀÜŪ±Æ¶Á¤Ï¸«¤é¤ì¤Æ¤¤¤Ê¤¤¡£
¤³¤ì¤é¤Î¤³¤È¤«¤é¡¢ÆÃÄê¤Î¶Ø´÷¾É¾õ¤¬³Îǧ¤µ¤ì¤Ê¤¤¸Â¤ê¡¢Ç§²Ä¤µ¤ì¤¿¥ï¥¯¥Á¥ó¤Ç¤¢¤ì¤Ð¡¢Ç¥ÉؤؤΥ說¥Á¥ó»ÈÍѤϲÄǽ¤Ç¤¢¤ë¡¢¤È¤·¤Æ¤¤¤ë¡£

­¥2010ǯ¤ÎÆîȾµå¤Ç¤Î¥ï¥¯¥Á¥ó¿ä¾©³ô¤Ë¤Ä¤¤¤Æ

Æó¤Ä¤Î¥ª¥×¥·¥ç¥ó¤Ë¤Ä¤¤¤Æ¡¢¸¡Æ¤¤µ¤ì¤¿¡£

¤Ò¤È¤Ä¤Ï¡¢»°²Á¥ï¥¯¥Á¥ó(H1N1.H3N2.B·¿)¡¢
¤â¤¦¤Ò¤È¤Ä¤Ï¡¢Æó²Á¥ï¥¯¥Á¥ó(H3N2.B·¿)¤Ç¤¢¤ë¡£

¸å¼Ô¤Ë¤Ä¤¤¤Æ¤Ï¡¢¸½ºß¤Î¿··¿H1N1¥ï¥¯¥Á¥ó¤òÊ䤦·Á¤Ç¤ÎÀܼï¤È¤Ê¤ë¡£
ÀìÌç²È¥°¥ë¡¼¥×¤È¤·¤Æ¤Ï¡¢Î¾¼Ô¤Î¥ª¥×¥·¥ç¥ó¤È¤â²Äǽ¤ÊÁªÂò¤Ç¤¢¤ë¡¢¤È¤·¤¿¡£

°Ê¾å

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£